

NEW ZEALAND DATA SHEET

TEVIMBRA® (tislelizumab (rch))

1 PRODUCT NAME

TEVIMBRA tislelizumab 100 mg/10 mL concentrate for solution for infusion

2 QUALITATIVE AND QUANTITATIVE COMPOSITION

Each TEVIMBRA 10 mL single dose vial contains 100 mg of tislelizumab in 10 mL solution, with a concentration of 10 mg/mL.

Tislelizumab is produced in Chinese hamster ovary cells by recombinant DNA technology.

Excipient(s) with known effect

Each mL of concentrate for solution for infusion contains 0.069 mmol (or 1.6 mg) sodium. For the full list of excipients, see section 6.1 List of excipients.

3 PHARMACEUTICAL FORM

Concentrate for solution for infusion.

Clear to slightly opalescent, colorless to slightly yellow solution.

The solution has a pH of approximately 6.5 and an osmolality of approximately 270 - 330 mOsm/kg.

4 CLINICAL PARTICULARS

4.1 THERAPEUTIC INDICATIONS

Oesophageal squamous cell carcinoma (OSCC)

TEVIMBRA in combination with platinum-based chemotherapy is indicated for the first-line treatment of patients with unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma with a PD-L1 expression $\geq 1\%$.

TEVIMBRA as monotherapy is indicated for the treatment of adult patients with unresectable, recurrent, locally advanced or metastatic oesophageal squamous cell carcinoma after prior chemotherapy.

Non-small cell lung cancer (NSCLC)

TEVIMBRA in combination with pemetrexed and platinum containing chemotherapy is indicated for the first-line treatment of patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC), with PD-L1 expression $\geq 50\%$ but no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations.

TEVIMBRA in combination with carboplatin and either paclitaxel or nab-paclitaxel is indicated for the first-line treatment of patients with locally advanced or metastatic squamous NSCLC.

TEVIMBRA as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy.

Gastric/Gastro-oesophageal Junction (G/GOJ) Adenocarcinoma

TEVIMBRA in combination with platinum and fluoropyrimidine-based chemotherapy, is indicated for the first-line treatment of adult patients with HER-2 negative locally advanced unresectable or metastatic gastric or gastro-oesophageal junction (G/GOJ) adenocarcinoma with a PD-L1 expression $\geq 1\%$.

4.2 DOSE AND METHOD OF ADMINISTRATION

TEVIMBRA should be administered under the supervision of a physician experienced in the use of cancer therapy.

TEVIMBRA is for single use in one patient only. Discard any residue after use.

Dosage

The recommended dose of TEVIMBRA is shown in Table 1.

The first infusion should be administered over 60 minutes. If this is well tolerated, the subsequent infusions may be administered over a period of 30 minutes.

When TEVIMBRA is used in combination, refer to the full prescribing information of the combination therapy. When administering TEVIMBRA in combination with chemotherapy, administer TEVIMBRA before chemotherapy when both are given on the same day.

Table 1 Recommended dose for TEVIMBRA

Indication	Recommended dose and schedule	Duration of treatment
TEVIMBRA monotherapy		
Second-line OSCC	150 mg every 2 weeks or 200 mg every 3 weeks or 300 mg every 4 weeks	Until disease progression or unacceptable toxicity. For patients who are considered to be deriving clinical benefit despite initial evidence of disease progression, it is recommended to continue TEVIMBRA treatment until disease progression is confirmed.
Second-line NSCLC	200 mg every 3 weeks	
TEVIMBRA combination therapy		
First-line OSCC	150 mg every 2 weeks or 200 mg every 3 weeks or 300 mg every 4 weeks	Until disease progression or unacceptable toxicity. For patients who are considered to be deriving clinical benefit despite initial evidence of disease progression, it is recommended to continue TEVIMBRA treatment until disease progression is confirmed.
First-line G/GOJ		
First-line NSCLC	200 mg every 3 weeks	

Treatment modifications for adverse drug reactions

No dose reductions of TEVIMBRA as monotherapy or in combination therapy are recommended. Withhold or permanently discontinue TEVIMBRA depending on the severity of the adverse drug reaction (ADR).

Recommended treatment modifications to manage immune-related ADRs are provided in Table 2.

Detailed guidelines for the management of immune-related adverse reactions are described in section 4.4 Special warnings and precautions for use.

Table 2 Recommended treatment modifications for TEVIMBRA

Immune-related ADR	Severity¹	TEVIMBRA treatment modification
Pneumonitis	Grade 2	Withhold ²
	Recurrent Grade 2; Grade 3 or 4	Permanently discontinue
Hepatitis	ALT or AST >3 and up to 8 times ULN (or) total bilirubin >1.5 and up to 3 times ULN	Withhold ²
	ALT or AST >8 times ULN (or) total bilirubin >3 times ULN	Permanently discontinue
Rash	Grade 3	Withhold ²
	Grade 4	Permanently discontinue
Severe cutaneous adverse reactions (SCARs)	Suspected SCARs, including SJS or TEN	Withhold ² For suspected SCARs (SJS or TEN), do not resume unless SJS/TEN has been ruled out in consultation with appropriate specialist.
	Confirmed SCARs, including SJS or TEN	Permanently discontinue
Colitis	Grade 2 or 3	Withhold ²
	Recurrent Grade 3; Grade 4	Permanently discontinue
Myositis/Rhabdomyolysis	Grade 2 or 3	Withhold ²
	Recurrent Grade 3; Grade 4	Permanently discontinue
Endocrinopathies	Hypothyroidism	Hypothyroidism may be managed with replacement therapy without treatment interruption
	Grade 3 or 4 adrenal insufficiency or symptomatic hypophysitis; Hyperthyroidism Grade \geq 3	Withhold ² Grade 3 or Grade 4 that improved to Grade \leq 2 and are controlled with HRT, if indicated, continuation of TEVIMBRA may be considered after corticosteroid taper, if needed. Otherwise, treatment should be discontinued.
	Diabetes mellitus associated with Grade \geq 3 hyperglycemia	Withhold ² Grade 3 or 4 that improved to

Immune-related ADR	Severity¹	TEVIMBRA treatment modification
	(glucose >250 mg/dL or >13.9 mmol/L) or associated with ketoacidosis	Grade ≤2, with insulin therapy, if indicated, continuation of TEVIMBRA may be considered once metabolic control is achieved. Otherwise, treatment should be discontinued.
	Grade 2 adrenal insufficiency and hypophysitis	Consider withholding treatment until controlled by HRT.
Nephritis with renal dysfunction	Grade 2 (creatinine >1.5 to 3 times baseline or >1.5 to 3 times ULN)	Withhold ²
	Grade 3 (creatinine >3 times baseline or >3 to 6 times ULN) Grade 4 (creatinine >6 times ULN)	Permanently discontinue
Myocarditis	Grade 2, 3, or 4	Permanently discontinue
Neurological toxicities	Grade 2	Withhold ²
	Grade 3 or 4	Permanently discontinue
Pancreatitis	Grade 3 pancreatitis or Grade 3 or Grade 4 serum amylase or lipase levels increased (>2 times ULN)	Withhold ²
	Grade 4	Permanently discontinue
Other immune-related ADRs	Grade 3	Withhold ²
	Recurrent Grade 3; Grade 4	Permanently discontinue
Other ADRs		
Infusion-related reactions	Grade 1	Consider premedication for prophylaxis of subsequent infusion reactions. Slow the rate of infusion by 50%.
	Grade 2	Interrupt infusion ³
	Grade 3 or 4	Permanently discontinue

ALT = alanine aminotransferase, AST = aspartate aminotransferase, BSA = body surface area, HRT = hormone replacement therapy, SJS = Stevens-Johnson syndrome, TEN = toxic epidermal necrolysis, ULN = upper limit of normal.

¹ Toxicity grades are in accordance with National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4).

² Resume in patients with complete or partial resolution (Grades 0 to 1) after corticosteroid taper. Permanently discontinue if no complete or partial resolution within 12 weeks of initiating corticosteroids or inability to reduce prednisone to 10 mg per day or less (or equivalent) within 12 weeks of initiating corticosteroids.

³ Resume infusion if resolved or decreased to Grade 1 and slow the rate of infusion by 50%. Consider premedication for prophylaxis of subsequent infusion-related reactions.

Special populations

Patients with Renal Impairment

Based on population pharmacokinetic analysis, no dose adjustment of TEVIMBRA is necessary in patients with mild or moderate renal impairment. Data from patients with severe renal impairment are too limited to draw conclusions for this population (see section 5.2 Pharmacokinetic properties).

Patients with Hepatic Impairment

Based on population pharmacokinetic analysis, no dose adjustment of TEVIMBRA is necessary in patients with mild or moderate hepatic impairment. Data from patients with severe hepatic impairment are too limited to draw conclusions for this population (see section 5.2 Pharmacokinetic properties).

Use in Children

The efficacy and safety of TEVIMBRA has not been established in patients below 18 years.

Use in the Elderly

No dose adjustment of TEVIMBRA is required in patients ages 65 years or above (see section 5.2 Pharmacokinetic properties).

Method of administration

TEVIMBRA is for intravenous infusion use only.

When TEVIMBRA is administered in combination with chemotherapy, it should be administered before chemotherapy when both are given on the same day. Refer to the New Zealand Data Sheet(s) for the chemotherapy administered in combination with TEVIMBRA.

Instructions for use and handling

Vials are for single use only. Each vial contains 100 mg of tislelizumab.

The diluted solution for infusion should be prepared by a healthcare professional using aseptic technique.

Preparation of solution for infusion

1. Remove the required number of vials from the refrigerator, taking care not to shake them.
2. Inspect each vial visually for particulate matter and discoloration prior to administration. The concentrate is a clear to slightly opalescent, colorless to slightly yellowish solution. Do not use a vial if the solution is cloudy or if visible particles or discoloration are observed.
3. Invert the vials gently, without shaking. Withdraw the required volume from the vial(s) and transfer into an intravenous (I.V.) infusion bag containing sodium chloride 9 mg/mL (0.9%) to prepare a diluted solution with a final concentration ranging from 1 to 5 mg/mL. Mix diluted solution by gentle inversion to avoid foaming or excessive shearing of the solution.

Administration

1. Administer the diluted tislelizumab solution by I.V. infusion through an intravenous administration line with a sterile, non-pyrogenic, low-protein binding 0.2 micron or 0.22 micron in-line or add-on filter, with a surface area of approximately 10 cm².
2. For 150 mg and 200 mg, the first infusion should be delivered over 60 minutes. If well tolerated, subsequent infusions may be administered over 30 minutes. For 300 mg, the first infusion should be delivered over 90 minutes. If this is well tolerated, the second infusion should be administered

over 60 minutes. If the second infusion is well tolerated, subsequent infusions should be administered over 30 minutes.

3. Other drugs should not be co-administered through the same infusion line.
4. Tislelizumab must not be administered as an intravenous push or single bolus injection.
5. TEVIMBRA does not contain any preservatives. It is recommended to prepare the solution immediately after taking it out of the refrigerator. From a microbiological point of view, once infusion is prepared, it is recommended to use the solution immediately after dilution. The diluted solution can be stored at 2°C to 8°C (36°F to 46°F) for up to 24 hours. The 24 hours include storage of the diluted solution under refrigeration (2 to ~8°C) for no more than 20 hours, and time required for returning to room temperature (25°C and below) as well as completing the infusion within 4 hours.
6. The diluted solution must not be frozen.
7. The intravenous line must be flushed at the end of the infusion.

4.3 CONTRAINDICATIONS

Hypersensitivity to tislelizumab or any of the excipients listed in section 6.1 List of excipients.

4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE

Immune-related adverse drug reactions

Severe, including fatal, cases of pneumonitis and hepatitis have been reported. Most immune-related adverse reactions occurring during treatment with TEVIMBRA were reversible and managed with interruptions of TEVIMBRA, administration of corticosteroids and/or supportive care.

Immune-related adverse reactions have also occurred after the last dose of TEVIMBRA.

Immune-related adverse reactions affecting more than one body system can occur simultaneously.

For suspected immune-related adverse reactions, adequate evaluation to confirm aetiology or exclude alternative aetiologies, including infection, should be ensured. Based on the severity of the adverse reaction, TEVIMBRA should be withheld and corticosteroids administered. Administration of other systemic immunosuppressants can be considered in patients whose immune-related adverse reactions are not controlled with corticosteroid therapy (see sections 4.2 Dose and method of administration and 4.8 Adverse effects (Undesirable effects)).

Patients with pre-existing autoimmune disease (AID)

In patients with pre-existing autoimmune disease (AID), data from observational studies suggest that the risk of immune-mediated adverse reactions following immune checkpoint inhibitor therapy may be increased as compared with the risk in patients without pre-existing AID. In addition, flares of the underlying AID were frequent, but the majority were mild and manageable.

Immune-related pneumonitis

Immune-related pneumonitis, including fatal cases, has been reported in patients receiving TEVIMBRA. Patients should be monitored for signs and symptoms of pneumonitis. Patients with suspected pneumonitis should be evaluated with radiographic imaging and infectious or disease-related aetiologies should be excluded.

Patients with immune-related pneumonitis should be managed according to treatment modifications in Table 2 (see section 4.2 Dose and method of administration) as well as applicable current local treatment guidelines.

Immune-related hepatitis

Immune-related hepatitis has been reported in patients treated with TEVIMBRA, including fatal cases. Patients should be monitored for signs and symptoms of hepatitis and changes in liver function. Liver function tests (LFTs) should be performed at baseline and periodically during treatment.

Patients with immune-related hepatitis should be managed according to treatment modifications in Table 2 (see section 4.2 Dose and method of administration) as well as applicable current local treatment guidelines.

Immune-related skin reactions

Immune-related skin rash or dermatitis have been reported in patients receiving TEVIMBRA. Patients should be monitored for signs and symptoms of suspected skin reactions and other causes should be excluded. Based on the severity of the skin adverse reactions, TEVIMBRA should be withheld or permanently discontinued as recommended in Table 2 (see section 4.2 Dose and method of administration) as well as per applicable current local treatment guidelines.

Cases of severe cutaneous adverse reactions (SCARs) including erythema multiforme (EM), Stevens-Johnson-Syndrome (SJS) and toxic epidermal necrolysis (TEN), some with fatal outcome, have been reported in patients receiving TEVIMBRA (see section 4.8 Adverse Effects (Undesirable Effects)). Patients should be monitored for signs or symptoms of SCARs (e.g., a prodrome of fever, flu-like symptoms, mucosal lesions, or progressive skin rash) and other causes should be excluded. For suspected SCARs, TEVIMBRA should be withheld, and the patient should be referred to specialized care for assessment and treatment. If SCARs is confirmed, TEVIMBRA should be permanently discontinued (see section 4.2 Dose and method of administration).

Immune-related colitis

Immune-related colitis, frequently associated with diarrhea, has been reported in patients treated with TEVIMBRA. Patients should be monitored for signs and symptoms of colitis. Infectious and disease-related aetiologies should be excluded.

Patients with immune-related colitis should be managed according to treatment modifications in Table 2 (see section 4.2 Dose and method of administration) as well as per applicable current local treatment guidelines.

Immune-related endocrinopathies

Immune-related endocrinopathies, including thyroid disorders, adrenal insufficiency, hypophysitis and diabetes mellitus, have been reported in patients treated with TEVIMBRA, which may require supportive treatment.

Patients with immune-related endocrinopathies should be managed according to treatment modifications as recommended in Table 2 (see section 4.2 Dose and method of administration) as well as applicable local treatment guidelines.

Thyroid disorders

Thyroid disorders, including hyperthyroidism, hypothyroidism and thyroiditis have been reported in patients treated with TEVIMBRA. Thyroiditis can present with or without other forms of endocrinopathy. Hypothyroidism can follow hyperthyroidism. Patients should be monitored for changes in thyroid function (at the start of treatment, periodically during treatment and as indicated based on clinical evaluation) and clinical signs and symptoms of thyroid disorders. Hypothyroidism

may be managed with hormone replacement therapy without treatment interruption and without corticosteroids. Hyperthyroidism may be managed symptomatically.

Adrenal insufficiency

Adrenal insufficiency has been reported in patients treated with TEVIMBRA. Patients should be monitored for signs and symptoms of adrenal insufficiency. Monitoring of adrenal function and hormone levels should be considered. Corticosteroids and hormone replacement should be administered as clinically indicated.

Hypophysitis/hypopituitarism

Hypophysitis/hypopituitarism has been reported in patients treated with TEVIMBRA. Hypophysitis can cause hypopituitarism. Patients should be monitored for signs and symptoms of hypophysitis/hypopituitarism. Monitoring of pituitary function and hormone levels should be considered. Corticosteroids and hormone replacement should be administered as clinically indicated.

Diabetes mellitus

Diabetes mellitus, including diabetic ketoacidosis has been reported in patients treated with TEVIMBRA. Patients should be monitored for hyperglycaemia or other signs and symptoms of diabetes. Insulin should be administered as clinically indicated for diabetes. In patients with severe hyperglycaemia or ketoacidosis (Grade ≥ 3), TEVIMBRA should be withheld and anti-hyperglycaemic treatment should be administered (see section 4.2 Dose and method of administration). Treatment with TEVIMBRA should be resumed when metabolic control is achieved.

Immune-related nephritis with renal dysfunction

Immune-related nephritis with renal dysfunction has been reported in patients treated with TEVIMBRA. Patients should be monitored for changes in renal function (elevated serum creatinine) and other causes of renal dysfunction should be excluded .

Patients with immune-related nephritis with renal dysfunction should be managed according to treatment modifications in Table 2 (see section 4.2 Dose and method of administration) as well as applicable current local treatment guidelines.

Other immune-related adverse reactions

Other clinically important immune-related adverse reactions were reported in patients treated with TEVIMBRA: myositis, myocarditis, arthritis, polymyalgia rheumatica, pericarditis, immune thrombocytopenia, encephalitis, myasthenia gravis, Sjogren's syndrome and Guillain-Barré syndrome (see 4.8 Adverse effects (Undesirable effects)).

Patients with other immune-related adverse reactions should be managed according to treatment modifications Table 2 (see section 4.2 Dose and method of administration) as well as applicable current local treatment guidelines.

Solid organ transplant rejection

Solid organ transplant rejection has been reported in the post-marketing setting in patients treated with PD-1 inhibitors. Treatment with TEVIMBRA may increase the risk of rejection in solid organ transplant recipients. The benefit of treatment with TEVIMBRA versus the risk of possible organ rejection should be considered in these patients.

Haemophagocytic lymphohistiocytosis (HLH)

Haemophagocytic lymphohistiocytosis (HLH) has been reported in patients receiving TEVIMBRA (see section 4.8 Adverse Effects). HLH is a life-threatening syndrome characterised by fever, skin rash, lymphadenopathy, hepato- and/or splenomegaly and cytopenias. Patients should be monitored for clinical signs and symptoms of HLH. For suspected HLH, TEVIMBRA must be interrupted. If HLH is confirmed, administration of TEVIMBRA should be discontinued.

Infusion-related reactions

Severe infusion-related reactions (Grade 3 or higher) have been reported in patients receiving TEVIMBRA (see 4.8 Adverse effects (Undesirable effects)). Cases of anaphylaxis, including anaphylactic reaction and anaphylactic shock, have been reported in the post-marketing setting. Patients should be monitored for signs and symptoms of infusion-related reactions.

Infusion-related reactions should be managed as recommended in Table 2 (see section 4.2 Dose and method of administration).

Embryo-fetal toxicity

There are no available data on the use of TEVIMBRA in pregnant women. Based on its mechanism of action, TEVIMBRA can cause fetal harm when administered to a pregnant woman.

Animal studies have demonstrated that inhibition of PD-1/PD-L1 pathway can lead to increased risk of immune-related rejection of the developing fetus resulting in fetal death.

Women should be advised of the potential risk to a fetus. TEVIMBRA should not be used during pregnancy and in women of childbearing potential not using effective contraception unless the clinical condition of the woman requires treatment with TEVIMBRA.

Sexually-active females of reproductive potential should be advised to use effective contraception (methods that result in less than 1% pregnancy rates) during treatment with TEVIMBRA and for at least 4 months after the last dose of tislelizumab (see section 4.6 Fertility, pregnancy and lactation).

Patients on controlled sodium diet

Each mL of this medicinal product contains 0.069 mmol (or 1.6 mg) sodium. This medicinal product contains 16 mg sodium per 10 mL vial, which is equivalent to 0.8% of the WHO recommended maximum daily intake of 2 g sodium for an adult.

4.5 INTERACTIONS WITH OTHER MEDICINES AND OTHER FORMS OF INTERACTIONS

Pharmacokinetic interaction studies have not been conducted. As monoclonal antibodies are not metabolised by cytochrome P450 (CYP) enzymes or other drug-metabolising enzymes, inhibition or induction of these enzymes by co-administered medicinal products is not anticipated to affect the pharmacokinetics of TEVIMBRA. TEVIMBRA is not expected to inhibit or induce CYP or other drug metabolising enzymes.

The use of systemic corticosteroids and other immunosuppressants at baseline, before starting TEVIMBRA, except for physiological doses of systemic corticosteroid (10 mg/day prednisone or equivalent), should be avoided because of their potential interference with the pharmacodynamic activity and efficacy. However, systemic corticosteroids and other immunosuppressants can be used after starting TEVIMBRA to treat immune-related adverse reactions (see section 4.4 Special warnings and precautions for use).

When TEVIMBRA is administered in combination with chemotherapy, TEVIMBRA should be administered before chemotherapy when both are given on the same day. Refer to the prescribing information for the chemotherapy administered in combination with TEVIMBRA for recommendations on corticosteroid use as premedication for the prevention of chemotherapy-related adverse reactions

4.6 FERTILITY, PREGNANCY AND LACTATION

Pregnancy

There are no available data on the use of tislelizumab in pregnant women. Based on its mechanism of action, there is a potential risk that administration of tislelizumab during pregnancy may result in fetal harm.

Animal reproduction studies have not been conducted with tislelizumab. However, in murine models of pregnancy, blockade of PD-1/PD-L1 signalling has been shown to disrupt tolerance to the fetus and to result in increased fetal loss.

Human IgG4 (immunoglobulins) are known to cross the placental barrier. Therefore, tislelizumab, being an IgG4 variant, has the potential to be transmitted from the mother to the developing fetus. Tislelizumab is not recommended during pregnancy unless the clinical benefit is expected to outweigh the potential risk to the fetus. Effective contraception (methods that result in less than 1% pregnancy rates) should be used for at least 4 months following the last dose of tislelizumab.

Breast-feeding

It is unknown whether tislelizumab is excreted in human milk but it is known that antibodies (including IgG4) are excreted in human milk. The effects of tislelizumab on breast-fed newborns/infants and on milk production are also unknown.

Because of the potential for serious adverse effects in breast-fed newborns/infants from tislelizumab, women should be advised not to breast-feed during treatment and for at least 4 months after the last dose of tislelizumab.

Fertility

No clinical data are available on the possible effects of tislelizumab on fertility. No reproductive and development toxicity studies have been conducted with tislelizumab.

4.7 EFFECTS ON ABILITY TO DRIVE AND USE MACHINES

TEVIMBRA has a minor influence on the ability to drive and use machines. In some patients, fatigue has been reported following administration of TEVIMBRA (see section 4.8 Adverse effects (Undesirable effects)).

4.8 ADVERSE EFFECTS (UNDESIRABLE EFFECTS)

Summary of the safety profile

Tislelizumab as monotherapy

The safety of tislelizumab as monotherapy is based on pooled data in 2,390 patients across multiple tumour types. The most common adverse drug reactions (ADR) (reported at a frequency >20%, with tislelizumab as monotherapy) were fatigue and increased aspartate aminotransferase. The most common grade 3/4 ADRs (reported at a frequency >2%, with tislelizumab as monotherapy) were increased aspartate aminotransferase, increased blood bilirubin, and fatigue.

ADRs leading to death were reported in 0.3% of patients and include pneumonitis (0.0%), hepatitis (0.1%) and dyspnoea (0.04%).

Tislelizumab as combination therapy

The safety of tislelizumab given in combination with chemotherapy is based on data in 1,950 patients treated with tislelizumab in combination with chemotherapy. Tislelizumab was administered at a dose of 200 mg every 3 weeks in combination with chemotherapy. The most common ADRs (reported at a frequency >20%, with tislelizumab in combination with chemotherapy) were fatigue, increased alanine aminotransferase, increased aspartate aminotransferase, diarrhoea and rash. The most common Grade 3/4 ADRs (reported at a frequency >2%, with tislelizumab in combination with chemotherapy) were fatigue, hypokalaemia, rash, increased alanine aminotransferase and increased aspartate aminotransferase.

ADRs leading to death were reported in 0.8% of patients. The ADRs leading to death were pneumonitis (0.3%), myocarditis (0.2%), dyspnoea (0.2%), hepatitis (0.1%), colitis (0.1%), hypokalaemia (0.1%) and myositis (0.1%).

Tabulated list of adverse reactions

Table 3 lists the incidence of adverse reactions in the monotherapy safety dataset and in patients treated with tislelizumab in combination with chemotherapy. ADRs are listed according to system organ class in MedDRA. Within each system organ class, the adverse drug reactions are presented in decreasing frequency.

Table 3 Adverse drug reactions with tislelizumab as monotherapy (N = 2,390) and in combination with chemotherapy (N = 1,950)

	Tislelizumab monotherapy N = 2,390	Tislelizumab combination therapy N = 1,950
Adverse drug reactions	All Grades n (%)	All Grades n (%)
Immune system disorders		
Sjogren's syndrome	0	2 (0.1)
Immune thrombocytopenia	0	1 (0.05)
Immune-mediated cystitis [#]	0	0
Haemophagocytic lymphohistiocytosis	1 (0.04)	2 (0.1)
Endocrine disorders		
Hypothyroidism ¹	306 (12.8)	311 (16.0)
Hyperthyroidism ²	147 (6.2)	152 (7.8)
Thyroiditis ³	27 (1.1)	14 (0.7)
Adrenal insufficiency ⁴	13 (0.5)	17 (0.9)
Hypophysitis ⁵	4 (0.2)	9 (0.5)
Metabolism and nutrition disorders		
Hyperglycaemia ⁶	191 (8.0)	204 (10.5)
Hypokalaemia ⁷	181 (7.6)	334 (17.1)*
Diabetes mellitus ⁸	23 (1.0)	32 (1.6)
Nervous system disorders		
Guillain-Barré syndrome	1 (0.04)	1 (0.05)
Encephalitis ⁹	0	1 (0.05)
Myasthenia gravis	0	1 (0.05)
Eye disorders		
Uveitis ¹⁰	6 (0.3)	3 (0.2)

Cardiac disorders		
Myocarditis ¹¹	14 (0.6)	23 (1.2)*
Pericarditis	2 (0.1)	1 (0.05)
Respiratory, thoracic and mediastinal disorders		
Cough	359 (15.0)	293 (15.0)
Dyspnoea	180 (7.5)*	180 (9.2)*
Pneumonitis ¹²	114 (4.8)*	151 (7.7)*
Gastrointestinal disorders		
Diarrhoea ¹³	281 (11.8)	395 (20.2)
Stomatitis ¹⁴	74 (3.1)	181 (9.3)
Colitis ¹⁵	22 (0.9)	20 (1.0)*
Pancreatitis ¹⁶	19 (0.8)	54 (2.8)
Coeliac disease	1 (0.04)	0
Hepatobiliary disorders		
Hepatitis ¹⁷	61 (2.6)*	73 (3.7)*
Skin and subcutaneous tissue disorders		
Rash ¹⁸	420 (17.6)	418 (21.4)
Pruritus	270 (11.3)	198 (10.2)
Vitiligo ¹⁹	15 (0.6)	6 (0.3)
Erythema multiforme	4 (0.2)	1 (0.05)
Stevens-Johnson syndrome	1 (0.04)	0
Toxic epidermal necrolysis ^{#,*}	0	0
Musculoskeletal and connective tissue disorders		
Arthralgia	229 (9.6)	227 (11.6)
Myalgia	48 (2.0)	80 (4.1)
Arthritis ²⁰	25 (1.1)	21 (1.1)
Myositis ²¹	18 (0.8)	14 (0.7)*
Renal and urinary disorders		
Nephritis ²²	6 (0.3)	8 (0.4)
General disorders and administration site conditions		
Fatigue ²³	614 (25.7)	796 (40.8)
Pyrexia ²⁴	355 (14.9)	360 (18.5)
Investigations		
Aspartate aminotransferase increased	503 (21.0)	590 (30.3)
Alanine aminotransferase increased	453 (19.0)	597 (30.6)
Blood bilirubin increased ²⁵	312 (13.1)	271 (13.9)
Blood alkaline phosphatase increased	175 (7.3)	132 (6.8)
Injury, poisoning and procedural complications		
Infusion-related reaction ²⁶	113 (4.7)	123 (6.3)

¹ Hypothyroidism includes preferred terms (PTs) of hypothyroidism, immune-mediated hypothyroidism, anti-thyroid antibody increased, thyroxine free decreased, tri-iodothyronine free decreased, tri-iodothyronine decreased, thyroid hormones decreased, primary hypothyroidism, central hypothyroidism and thyroxine decreased.

² Hyperthyroidism includes PTs of hyperthyroidism, immune-mediated hyperthyroidism, blood thyroid stimulating hormone decreased, tri-iodothyronine free increased, thyroxine free increased, thyroxine increased and tri-iodothyronine increased.

³ Thyroiditis includes PTs of thyroiditis, autoimmune thyroiditis, immune-mediated thyroiditis, silent thyroiditis and thyroiditis subacute.

⁴ Adrenal insufficiency includes PTs of adrenal insufficiency, Addison's disease, glucocorticoid deficiency, immune-mediated adrenal insufficiency, primary adrenal insufficiency and secondary adrenocortical insufficiency.

⁵ Hypophysitis includes PTs of hypopituitarism and lymphocytic hypophysitis.

⁶ Hyperglycaemia includes PTs of hyperglycaemia and blood glucose increased.

⁷ Hypokalaemia includes PTs of hypokalaemia and blood potassium decreased.

⁸ Diabetes mellitus includes PTs of diabetes mellitus, type 1 diabetes mellitus, diabetic ketoacidosis, diabetic ketosis, ketoacidosis and latent autoimmune diabetes in adults.

-
- ⁹ Encephalitis includes PT of immune-mediated encephalitis.
- ¹⁰ Uveitis includes PTs of uveitis, iritis, iridocyclitis and chorioretinitis.
- ¹¹ Myocarditis includes PTs of myocarditis, immune-mediated myocarditis and autoimmune myocarditis.
- ¹² Pneumonitis includes PTs of pneumonitis, immune-mediated lung disease, interstitial lung disease and organising pneumonia.
- ¹³ Diarrhoea includes PTs of diarrhoea and frequent bowel movements.
- ¹⁴ Stomatitis includes PTs of stomatitis, mouth ulceration, oral mucosa erosion and aphthous ulcer.
- ¹⁵ Colitis includes PTs of colitis, immune-mediated enterocolitis, colitis ulcerative and autoimmune colitis.
- ¹⁶ Pancreatitis includes PTs of amylase increased, lipase increased, pancreatitis, autoimmune pancreatitis, and pancreatitis acute.
- ¹⁷ Hepatitis includes PTs of hepatitis, hepatotoxicity, hepatitis function abnormal, immune-mediated hepatitis drug-induced liver injury, liver injury and autoimmune hepatitis.
- ¹⁸ Rash includes PTs of rash, rash maculo-papular, eczema, rash erythematous, dermatitis, dermatitis exfoliative, dermatitis allergic, rash papular, urticaria, erythema, skin exfoliation, drug eruption, rash macular, psoriasis, rash pustular, dermatitis acneiform, rash pruritic, lichenoid keratosis, hand dermatitis, immune mediated dermatitis, autoimmune dermatitis, rash follicular, acute febrile neutrophilic dermatosis, erythema nodosum, granulomatous dermatitis, nodular rash, pemphigoid and transient acantholytic dermatosis.
- ¹⁹ Vitiligo includes PTs of vitiligo, skin hypopigmentation, skin depigmentation, and leukoderma.
- ²⁰ Arthritis includes PTs of arthritis, immune-mediated arthritis and polyarthritis.
- ²¹ Myositis includes PTs of myositis, immune-mediated myositis, rhabdomyolysis, and polymyalgia rheumatica.
- ²² Nephritis includes PTs of nephritis, focal segmental glomerulosclerosis, glomerulonephritis membranous, tubulointerstitial nephritis, immune-mediated renal disorder and immune-mediated nephritis.
- ²³ Fatigue includes PTs of fatigue, asthenia, malaise and lethargy.
- ²⁴ Pyrexia included reports of body temperature increased, and pyrexia.
- ²⁵ Blood bilirubin increased includes PTs of blood bilirubin increased, bilirubin conjugated increased, blood bilirubin unconjugated increased and hyperbilirubinaemia.
- ²⁶ Infusion-related reaction includes PTs of rash, infusion-related reaction, chills, rash erythematous, rhinitis allergic, urticaria, drug hypersensitivity, laryngeal oedema, laryngeal obstruction, rash macular, rash pruritic, swelling face, anaphylactic reaction, corneal oedema, dermatitis allergic, drug eruption, face oedema, gingival swelling, lip oedema, lip swelling, mouth swelling, pruritus allergic, tongue oedema, hypersensitivity and type I hypersensitivity. Cases of anaphylaxis, including anaphylactic reaction and anaphylactic shock have been reported in the post-marketing setting.
- * Including fatal outcomes.
- #Reported in the post-marketing setting.
-

Adverse events by indication

Oesophageal squamous cell carcinoma (OSCC)

First-line Treatment of Unresectable, Locally Advanced, or Metastatic Oesophageal Carcinoma

The safety of tislelizumab in combination with chemotherapy was evaluated in RATIONALE-306, a randomised, placebo-controlled, multicenter, double-blind trial in patients with unresectable, locally advanced, or metastatic OSCC.

Patients were randomised (1:1) to receive either tislelizumab 200 mg or placebo plus a chemotherapy doublet regimen. The chemotherapy doublet regimens consist of:

- Platinum (cisplatin [60 to 80 mg/m² IV, on Day 1] or oxaliplatin [130 mg/m² IV, on Day 1]) and a fluoropyrimidine (5-FU [750 to 800 mg/m² IV, on Day 1 to 5] or capecitabine [1000 mg/m² orally twice daily, on Day 1 to 14]), or
- Platinum (cisplatin [60 to 80 mg/m² IV, on Day 1 or 2] or oxaliplatin [130 mg/m² IV, on Day 1 or 2]) and (paclitaxel 175 mg/m² IV, on Day 1)

The median tislelizumab/placebo duration of exposure was 6.41 months (range, 0.1 to 38.3 months) in the tislelizumab plus chemotherapy arm.

The most common adverse events ($\geq 30\%$) were anaemia, neutrophil count decreased, decreased appetite, white blood cell count decreased, nausea, and constipation.

The most common \geq Grade 3 adverse events ($\geq 5\%$) were neutrophil count decreased, anaemia, hyponatraemia, white blood cell count decreased, hypokalaemia, neutropenia, dysphagia, pneumonia, decreased appetite, and fatigue.

Serious adverse events occurred in 48.1% of patients; the most frequent serious adverse events ($\geq 2\%$) were dysphagia, pneumonia, diarrhoea, and oesophageal stenosis.

Fatal adverse events occurred in 5.2% of patients who received tislelizumab, including acquired trachea-oesophageal fistula, brain injury, electrolyte imbalance, gastrointestinal haemorrhage, multiple organ dysfunction syndrome, myocarditis, pneumonia, pneumonia aspiration, pulmonary embolism, pulmonary tuberculosis, respiratory failure, sepsis, sudden death, and traumatic intracranial haemorrhage (1 patient each), and death (2 patients).

Adverse events leading to discontinuation of tislelizumab occurred in 13.0% of patients; the most common adverse events resulting in permanent discontinuation ($\geq 1\%$) was pneumonitis.

Adverse events leading to the treatment modification of tislelizumab occurred in 52.5% of patients; the most common adverse events leading to treatment modification of tislelizumab ($\geq 5\%$) were neutrophil count decreased and pneumonia.

Adverse events are listed in Table 4.

Table 4 Adverse events ($\geq 10\%$) in Patients Receiving tislelizumab in RATIONALE-306

System Organ Class Preferred Term	Tislelizumab + Chemotherapy (N = 324)		Placebo + Chemotherapy (N = 321)	
	All Grades n (%)	\geq Grade 3 n (%)	All Grades n (%)	\geq Grade 3 n (%)
Gastrointestinal disorders	264 (81.5)	72 (22.2)	249 (77.6)	53 (16.5)
Nausea	123 (38.0)	9 (2.8)	136 (42.4)	5 (1.6)
Constipation	98 (30.2)	0 (0.0)	100 (31.2)	1 (0.3)
Diarrhoea	91 (28.1)	14 (4.3)	78 (24.3)	6 (1.9)
Vomiting	72 (22.2)	5 (1.5)	88 (27.4)	8 (2.5)
Stomatitis	63 (19.4)	13 (4.0)	48 (15.0)	7 (2.2)
Dysphagia	44 (13.6)	20 (6.2)	35 (10.9)	13 (4.0)
Investigations	261 (80.6)	127 (39.2)	247 (76.9)	130 (40.5)
Neutrophil count decreased	154 (47.5)	100 (30.9)	156 (48.6)	107 (33.3)
White blood cell count decreased	143 (44.1)	35 (10.8)	157 (48.9)	50 (15.6)
Weight decreased	94 (29.0)	6 (1.9)	89 (27.7)	2 (0.6)
Platelet count decreased	62 (19.1)	9 (2.8)	55 (17.1)	3 (0.9)

	Tislelizumab + Chemotherapy (N = 324)		Placebo + Chemotherapy (N = 321)	
System Organ Class Preferred Term	All Grades n (%)	>= Grade 3 n (%)	All Grades n (%)	>= Grade 3 n (%)
Aspartate aminotransferase increased	52 (16.0)	7 (2.2)	37 (11.5)	4 (1.2)
Alanine aminotransferase increased	50 (15.4)	5 (1.5)	42 (13.1)	5 (1.6)
Blood creatinine increased	45 (13.9)	1 (0.3)	30 (9.3)	1 (0.3)
Metabolism and nutrition disorders	234 (72.2)	82 (25.3)	212 (66.0)	62 (19.3)
Decreased appetite	144 (44.4)	18 (5.6)	125 (38.9)	7 (2.2)
Hypoalbuminaemia	74 (22.8)	0 (0.0)	60 (18.7)	0 (0.0)
Hyponatraemia	72 (22.2)	36 (11.1)	60 (18.7)	18 (5.6)
Hypokalaemia	65 (20.1)	28 (8.6)	55 (17.1)	22 (6.9)
Hypochloraemia	36 (11.1)	4 (1.2)	31 (9.7)	1 (0.3)
Blood and lymphatic system disorders	231 (71.3)	85 (26.2)	199 (62.0)	76 (23.7)
Anaemia	197 (60.8)	56 (17.3)	180 (56.1)	50 (15.6)
Neutropenia	53 (16.4)	24 (7.4)	47 (14.6)	32 (10.0)
Leukopenia	34 (10.5)	9 (2.8)	30 (9.3)	10 (3.1)
General disorders and administration site conditions	198 (61.1)	39 (12.0)	201 (62.6)	31 (9.7)
Fatigue	64 (19.8)	17 (5.2)	57 (17.8)	9 (2.8)
Pyrexia	52 (16.0)	1 (0.3)	39 (12.1)	2 (0.6)
Asthenia	43 (13.3)	7 (2.2)	45 (14.0)	3 (0.9)
Malaise	43 (13.3)	6 (1.9)	52 (16.2)	3 (0.9)
Nervous system disorders	163 (50.3)	20 (6.2)	155 (48.3)	16 (5.0)
Peripheral sensory neuropathy	75 (23.1)	10 (3.1)	62 (19.3)	7 (2.2)
Hypoaesthesia	34 (10.5)	1 (0.3)	40 (12.5)	1 (0.3)
Skin and subcutaneous tissue disorders	149 (46.0)	17 (5.2)	114 (35.5)	4 (1.2)
Alopecia	60 (18.5)	0 (0.0)	63 (19.6)	0 (0.0)
Pruritus	43 (13.3)	1 (0.3)	21 (6.5)	0 (0.0)
Rash	37 (11.4)	7 (2.2)	23 (7.2)	0 (0.0)
Respiratory, thoracic and mediastinal disorders	143 (44.1)	22 (6.8)	124 (38.6)	21 (6.5)
Cough	51 (15.7)	2 (0.6)	38 (11.8)	0 (0.0)
Infections and infestations	114 (35.2)	31 (9.6)	87 (27.1)	34 (10.6)
Pneumonia	42 (13.0)	19 (5.9)	35 (10.9)	20 (6.2)
Endocrine disorders	51 (15.7)	5 (1.5)	16 (5.0)	0 (0.0)
Hypothyroidism	33 (10.2)	0 (0.0)	14 (4.4)	0 (0.0)

Second-line Treatment of Unresectable, Locally Advanced, or Metastatic Oesophageal Carcinoma

The data described below reflect exposure to tislelizumab in 255 patients with oesophageal squamous cell carcinoma in RATIONALE-302. Patients received 200 mg of tislelizumab via intravenous infusion every 3 weeks [see 5.1 Pharmacodynamic properties (Clinical trials)]. The median duration of exposure to tislelizumab was 2.8 months (range: 0.2 to 28.3 months).

The most common adverse events ($\geq 20\%$) were anaemia, fatigue (including asthenia, fatigue, and malaise), and weight decreased.

The most common \geq Grade 3 adverse events ($\geq 2\%$) were dysphagia, anaemia, hyponatremia, pneumonia, dyspnoea, lymphocyte count decreased, hypertension, fatigue (including asthenia, fatigue, and malaise), and pneumonitis (including pneumonitis and interstitial lung disease).

Serious adverse events occurred in 41.2% of patients; the most frequent serious adverse events ($\geq 2\%$) were pneumonia, dysphagia, pneumonitis (including pneumonitis and immune-mediated pneumonitis), and oesophageal obstruction.

Fatal adverse events (excluding death due to disease under study) occurred in 5.5% of patients who received tislelizumab, including bronchiectasis, hemoptysis, pulmonary arterial hypertension, pulmonary embolism, pulmonary hemorrhage, sudden death, cardio-respiratory arrest, upper gastrointestinal hemorrhage, platelet count decreased (1 patient each), death due to an unknown cause (2 patients), and pneumonia (3 patients).

Adverse events leading to discontinuation of tislelizumab occurred in 19.2% of patients; the most common adverse events resulting in permanent discontinuation ($\geq 1\%$) were pneumonitis (including pneumonitis and immune-mediated pneumonitis), pneumonia, and upper gastrointestinal hemorrhage.

Adverse events leading to the interruption of tislelizumab occurred in 22.7% of patients; the most common adverse events leading to interruption of tislelizumab ($\geq 2\%$) were pneumonia, pneumonitis (including pneumonitis, interstitial lung disease, and immune-mediated pneumonitis) and fatigue (including asthenia and fatigue).

Adverse events are listed in Table 5.

Table 5 Adverse events ($\geq 10\%$) in Patients Receiving tislelizumab in RATIONALE-302

System Organ Class Preferred Term	Tislelizumab (N = 255)		ICC (N = 240)	
	All Grades n (%)	\geq Grade 3 n (%)	All Grades n (%)	\geq Grade 3 n (%)
Blood and Lymphatic system disorders	92 (36.1)	18 (7.1)	139 (57.9)	55 (22.9)
Anaemia	78 (30.6)	15 (5.9)	107 (44.6)	26 (10.8)
Endocrine Disorders	39 (15.3)	1 (0.4)	2 (0.8)	0 (0.0)
Hypothyroidism	29 (11.4)	1 (0.4)	1 (0.4)	0 (0.0)
Gastrointestinal Disorders	149 (58.4)	36 (14.1)	171 (71.3)	43 (17.9)
Constipation	39 (15.3)	0 (0.0)	45 (18.8)	1 (0.4)
Nausea	36 (14.1)	1 (0.4)	72 (30.0)	8 (3.3)
Diarrhoea	32 (12.5)	3 (1.2)	77 (32.1)	15 (6.3)
Dysphagia	28 (11.0)	16 (6.3)	20 (8.3)	7 (2.9)
Vomiting	27 (10.6)	2 (0.8)	48 (20.0)	9 (3.8)
General Disorders and administration site conditions	116 (45.5)	9 (3.5)	147 (61.3)	18 (7.5)
Fatigue ^a	72 (28.2)	5 (2.0)	110 (45.8)	15 (6.3)
Pyrexia	41 (16.1)	1 (0.4)	34 (14.2)	0 (0.0)
Infections and Infestations	75 (29.4)	17 (6.7)	75 (31.3)	24 (10.0)
Pneumonia	36 (14.1)	11 (4.3)	27 (11.3)	14 (5.8)
Investigations	129 (50.6)	25 (9.8)	166 (69.2)	90 (37.5)

System Organ Class Preferred Term	Tislelizumab (N = 255)		ICC (N = 240)	
	All Grades n (%)	≥ Grade 3 n (%)	All Grades n (%)	≥ Grade 3 n (%)
Weight decreased	59 (23.1)	3 (1.2)	45 (18.8)	0 (0.0)
Aspartate aminotransferase increased	37 (14.5)	3 (1.2)	11 (4.6)	1 (0.4)
Alanine aminotransferase	33 (12.9)	2 (0.8)	18 (7.5)	4 (1.7)
Metabolism and nutrition disorders	116 (45.5)	26 (10.2)	141 (58.8)	31 (12.9)
Decreased appetite	40 (15.7)	1 (0.4)	84 (35.0)	10 (4.2)
Hypoalbuminemia	34 (13.3)	2 (0.8)	30 (12.5)	2 (0.8)
Hyponatremia	32 (12.5)	14 (5.5)	33 (13.8)	10 (4.2)
Musculoskeletal and connective tissue disorders	66 (25.9)	5 (2.0)	61 (25.4)	4 (1.7)
Back pain	26 (10.2)	0 (0.0)	18 (7.5)	1 (0.4)
Respiratory, thoracic, and mediastinal disorders	104 (40.8)	20 (7.8)	81 (33.8)	16 (6.7)
Cough	43 (16.9)	0 (0.0)	28 (11.7)	1 (0.4)
Skin and subcutaneous tissue disorders	59 (23.1)	1 (0.4)	67 (27.9)	0 (0.0)
Rash ^b	33 (12.9)	1 (0.4)	15 (6.3)	0 (0.0)

ICC = Investigator chosen chemotherapy: paclitaxel vs docetaxel vs irinotecan

Adverse event Grades are evaluated based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v.4.03. Patients with multiple events for a given grouping term and system organ class are counted only once at the worst toxicity grade for the grouping term, and system organ class, respectively.

^a Fatigue includes Asthenia, Fatigue, Malaise.

^b Rash includes Dermatitis, Dermatitis acneiform, Dermatitis allergic, Eczema, Erythema, Psoriasis, Rash, Rash follicular, Rash maculo-papular, Rash pruritic.

Non-small cell lung cancer (NSCLC)

First-line treatment of metastatic non-squamous NSCLC in combination with pemetrexed and platinum chemotherapy

The data described below reflect exposure to tislelizumab in 222 patients with untreated locally advanced or metastatic non-squamous NSCLC in RATIONALE-304. Patients received tislelizumab 200 mg combined with pemetrexed 500 mg/m² and carboplatin AUC 5 mg/mL/min or cisplatin 75 mg/m² (T+PP arm) [see 5.1 Pharmacodynamic properties (Clinical trials)]. The median duration of exposure to tislelizumab was 34.14 weeks (range: 3.0 to 118.0 weeks).

The most common adverse events (≥50%) were anaemia, white blood cell count decreased, neutrophil count decreased, platelet count decreased, and alanine aminotransferase increased.

The most common ≥Grade 3 adverse events (≥5%) were neutropenia, anaemia, thrombocytopenia, leukopenia, neutrophil count decreased, white blood cell count decreased, platelet count decreased, and pneumonia.

Serious adverse events occurred in 39.2% of patients; the most frequent serious adverse events (≥2%) were pneumonitis, pneumonia, thrombocytopenia, platelet count decreased, pyrexia, and dyspnoea.

Fatal adverse events occurred in 4.1% of patients who received tislelizumab, including asphyxia, dyspnoea, atrial fibrillation, myocarditis, death, and cerebellar haemorrhage (1 patient each), and pneumonitis (3 patients).

Adverse events leading to discontinuation of tislelizumab occurred in 14.4% of patients; the most common adverse events resulting in permanent discontinuation ($\geq 1\%$) were pneumonitis, and immune-mediated enterocolitis.

Adverse events leading to the treatment modification of tislelizumab occurred in 64.0% of patients; the most common adverse events leading to treatment modification of tislelizumab ($\geq 5\%$) were anaemia, neutropenia, white blood cell count decreased, neutrophil count decreased, alanine aminotransferase increased, pneumonia, and pneumonitis.

Adverse events are listed in Table 6.

Table 6 Adverse Events ($\geq 20\%$) in Patients Receiving tislelizumab in RATIONALE-304

System Organ Class Preferred Term	T+PP (N = 222)		PP (N = 110)	
	All Grades n (%)	\geq Grade 3 n (%)	All Grades n (%)	\geq Grade 3 n (%)
Investigations	209 (94.1)	85 (38.3)	101 (91.8)	22 (20.0)
White blood cell count decreased	158 (71.2)	30 (13.5)	62 (56.4)	5 (4.5)
Neutrophil count decreased	146 (65.8)	57 (25.7)	55 (50.0)	14 (12.7)
Platelet count decreased	121 (54.5)	19 (8.6)	46 (41.8)	6 (5.5)
Alanine aminotransferase increased	115 (51.8)	8 (3.6)	50 (45.5)	3 (2.7)
Aspartate aminotransferase increased	102 (45.9)	4 (1.8)	51 (46.4)	0 (0.0)
Blood and lymphatic system disorders	201 (90.5)	87 (39.2)	97 (88.2)	38 (34.5)
Anaemia	186 (83.8)	33 (14.9)	85 (77.3)	13 (11.8)
Neutropenia	84 (37.8)	53 (23.9)	39 (35.5)	25 (22.7)
Thrombocytopenia	66 (29.7)	25 (11.3)	33 (30.0)	10 (9.1)
Leukopenia	65 (29.3)	24 (10.8)	32 (29.1)	12 (10.9)
Gastrointestinal disorders	155 (69.8)	10 (4.5)	74 (67.3)	1 (0.9)
Nausea	101 (45.5)	1 (0.5)	46 (41.8)	1 (0.9)
Vomiting	61 (27.5)	1 (0.5)	26 (23.6)	1 (0.9)
Constipation	54 (24.3)	0 (0.0)	26 (23.6)	0 (0.0)
Metabolism and nutrition disorders	145 (65.3)	17 (7.7)	65 (59.1)	4 (3.6)
Decreased appetite	79 (35.6)	3 (1.4)	36 (32.7)	2 (1.8)
General disorders and administration site conditions	135 (60.8)	6 (2.7)	59 (53.6)	6 (5.5)
Malaise	42 (18.9)	1 (0.5)	23 (20.9)	3 (2.7)
Respiratory, thoracic and mediastinal disorders	113 (50.9)	20 (9.0)	38 (34.5)	2 (1.8)
Skin and subcutaneous tissue disorders	74 (33.3)	3 (1.4)	29 (26.4)	1 (0.9)
Infections and infestations	70 (31.5)	20 (9.0)	26 (23.6)	9 (8.2)
Nervous system disorders	52 (23.4)	6 (2.7)	19 (17.3)	3 (2.7)
Musculoskeletal and connective tissue disorders	73 (32.9)	1 (0.5)	24 (21.8)	2 (1.8)

Abbreviations: T+PP, Tislelizumab+Pemetrexed+Platinum; PP, Pemetrexed+Platinum; Adverse event Grades were evaluated based on NCI-CTCAE (version 5.0). Patients with multiple events for a given Preferred Term and System Organ Class were counted only once at the maximum Grade for the preferred term and system organ class, respectively. First-line treatment of locally advanced or metastatic squamous NSCLC in combination with carboplatin and either paclitaxel or nab-paclitaxel chemotherapy

First-line treatment of metastatic squamous NSCLC in combination with paclitaxel and platinum chemotherapy

The data described below reflect exposure to tislelizumab in 238 patients with locally advanced or metastatic squamous NSCLC in RATIONALE-307. Patients receive tislelizumab 200 mg combined with paclitaxel 175 mg/m² and carboplatin AUC 5 mg/ml/min (T+PC arm, N=120), or tislelizumab 200 mg combined with nab-paclitaxel 100 mg/m² and carboplatin AUC 5 mg/mL/min (T+nPC arm, N=118) [see 5.1 Pharmacodynamic properties (Clinical trials)]. The median duration of exposure to tislelizumab was 40.21 weeks (range: 3.0 to 100.9 weeks) in Arm T+PC and 44.21 weeks (range: 3.0 to 105.0 weeks) in Arm T+nPC. The most common adverse events (≥50%) were anaemia, neutrophil count decreased, white blood cell count decreased, and alopecia in Arm T+PC, and anaemia, leukopenia, neutrophil count decreased, white blood cell count decreased, and alopecia in Arm T+nPC.

The most common ≥Grade 3 adverse events (≥5%) were neutrophil count decreased, white blood cell count decreased, platelet count decreased, neutropenia, anaemia, thrombocytopenia, leukopenia, and pneumonia in both Arm T+PC and Arm T+nPC.

Serious adverse events occurred in 43.3% of patients in Arm T+PC and 42.4% of patients in Arm T+nPC. The most frequent serious adverse events (≥2%) were pneumonitis, pneumonia, haemoptysis, and neutrophil count decreased in Arm T+PC, and pneumonitis, pneumonia, haemoptysis, febrile neutropenia, and neutrophil count decreased in Arm T+nPC.

Fatal adverse events occurred in 3.3% of patients in Arm T+PC and 5.9% of patients in Arm T+nPC, including cerebrovascular accident, hydrocephalus, haemoptysis, and respiratory failure (1 patient each) in Arm T+PC, and haemoptysis, respiratory failure, hepatic failure, pneumonia, and hypokalaemia (1 patient each) and death (2 patients) in Arm T+nPC.

Adverse events leading to discontinuation of tislelizumab occurred in 14.2% of patients in Arm T+PC and 12.7% of patients in Arm T+nPC; the most common adverse events resulting in permanent discontinuation (≥2 patients) were pneumonitis, and pneumonia in Arm T+PC, and immune-mediated pneumonitis, pneumonia, blood creatine phosphokinase increased, myocarditis, and death in Arm T+nPC.

Adverse events leading to the treatment modification of tislelizumab occurred in 47.5% of patients in Arm T+PC, and 79.7% of patients in Arm T+nPC; the most common adverse events leading to treatment modification of tislelizumab (≥5%) were anaemia, thrombocytopenia, leukopenia, platelet count decreased, neutrophil count decreased, alanine aminotransferase increased, white blood cell count decreased, aspartate aminotransferase increased, hypothyroidism, and pneumonia in Arm T+PC, and anaemia, thrombocytopenia, leukopenia, neutropenia, platelet count decreased, neutrophil count decreased, alanine aminotransferase increased, and white blood cell count decreased in Arm T+nPC.

Adverse events are listed in Table 7.

Table 7 Adverse Events (≥ 20%) in Patients Receiving tislelizumab in RATIONALE-307

System Organ Class Preferred Term	T+PC (N = 120)		T+nPC (N = 118)		PC (N = 117)	
	All Grades n (%)	≥Grade 3 n (%)	All Grades n (%)	≥Grade 3 n (%)	All Grades n (%)	≥Grade 3 n (%)
Blood and lymphatic system disorders	112 (93.3)	56 (46.7)	115 (97.5)	68 (57.6)	106 (90.6)	63 (53.8)
Anaemia	107 (89.2)	12 (10.0)	111 (94.1)	27 (22.9)	94 (80.3)	15 (12.8)
Leukopenia	58 (48.3)	19 (15.8)	66 (55.9)	30 (25.4)	57 (48.7)	22 (18.8)

System Organ Class Preferred Term	T+PC (N = 120)		T+nPC (N = 118)		PC (N = 117)	
	All Grades n (%)	≥Grade 3 n (%)	All Grades n (%)	≥Grade 3 n (%)	All Grades n (%)	≥Grade 3 n (%)
Neutropenia	53 (44.2)	40 (33.3)	50 (42.4)	32 (27.1)	56 (47.9)	47 (40.2)
Thrombocytopenia	35 (29.2)	8 (6.7)	49 (41.5)	15 (12.7)	33 (28.2)	7 (6.0)
Investigations	111 (92.5)	77 (64.2)	110 (93.2)	69 (58.5)	101 (86.3)	58 (49.6)
Neutrophil count decreased	78 (65.0)	64 (53.3)	72 (61.0)	54 (45.8)	68 (58.1)	53 (45.3)
White blood cell count decreased	67 (55.8)	28 (23.3)	68 (57.6)	32 (27.1)	62 (53.0)	28 (23.9)
Alanine aminotransferase increased	56 (46.7)	3 (2.5)	43 (36.4)	2 (1.7)	27 (23.1)	0 (0.0)
Aspartate aminotransferase increased	49 (40.8)	2 (1.7)	42 (35.6)	1 (0.8)	14 (12.0)	0 (0.0)
Platelet count decreased	44 (36.7)	6 (5.0)	52 (44.1)	16 (13.6)	29 (24.8)	2 (1.7)
Blood bilirubin increased	30 (25.0)	0 (0.0)	18 (15.3)	0 (0.0)	15 (12.8)	0 (0.0)
Metabolism and nutrition disorders	95 (79.2)	11 (9.2)	91 (77.1)	7 (5.9)	72 (61.5)	8 (6.8)
Decreased appetite	54 (45.0)	2 (1.7)	55 (46.6)	2 (1.7)	37 (31.6)	1 (0.9)
Hypoalbuminaemia	30 (25.0)	1 (0.8)	25 (21.2)	0 (0.0)	19 (16.2)	0 (0.0)
Hypokalaemia	26 (21.7)	3 (2.5)	20 (16.9)	2 (1.7)	16 (13.7)	2 (1.7)
Hyponatraemia	26 (21.7)	2 (1.7)	25 (21.2)	2 (1.7)	20 (17.1)	3 (2.6)
Skin and subcutaneous tissue disorders	89 (74.2)	6 (5.0)	94 (79.7)	4 (3.4)	74 (63.2)	0 (0.0)
Alopecia	78 (65.0)	0 (0.0)	82 (69.5)	0 (0.0)	72 (61.5)	0 (0.0)
Rash	26 (21.7)	4 (3.3)	28 (23.7)	2 (1.7)	4 (3.4)	0 (0.0)
Gastrointestinal disorders	77 (64.2)	5 (4.2)	90 (76.3)	2 (1.7)	60 (51.3)	3 (2.6)
Constipation	40 (33.3)	0 (0.0)	36 (30.5)	0 (0.0)	27 (23.1)	0 (0.0)
Nausea	37 (30.8)	1 (0.8)	54 (45.8)	0 (0.0)	35 (29.9)	1 (0.9)
Vomiting	28 (23.3)	1 (0.8)	27 (22.9)	0 (0.0)	20 (17.1)	2 (1.7)
General disorders and administration site conditions	77 (64.2)	5 (4.2)	70 (59.3)	3 (2.5)	62 (53.0)	5 (4.3)
Asthenia	30 (25.0)	0 (0.0)	24 (20.3)	0 (0.0)	24 (20.5)	1 (0.9)
Pyrexia	25 (20.8)	0 (0.0)	24 (20.3)	0 (0.0)	18 (15.4)	0 (0.0)
Malaise	24 (20.0)	3 (2.5)	19 (16.1)	1 (0.8)	19 (16.2)	0 (0.0)
Musculoskeletal and connective tissue disorders	74 (61.7)	5 (4.2)	59 (50.0)	1 (0.8)	51 (43.6)	1 (0.9)
Pain in extremity	40 (33.3)	3 (2.5)	18 (15.3)	0 (0.0)	27 (23.1)	0 (0.0)
Arthralgia	26 (21.7)	0 (0.0)	23 (19.5)	0 (0.0)	20 (17.1)	0 (0.0)
Nervous system disorders	68 (56.7)	7 (5.8)	38 (32.2)	1 (0.8)	45 (38.5)	2 (1.7)
Hypoaesthesia	27 (22.5)	0 (0.0)	13 (11.0)	0 (0.0)	20 (17.1)	0 (0.0)
Respiratory, thoracic and mediastinal disorders	59 (49.2)	9 (7.5)	69 (58.5)	13 (11.0)	39 (33.3)	3 (2.6)
Haemoptysis	24 (20.0)	2 (1.7)	20 (16.9)	4 (3.4)	13 (11.1)	0 (0.0)
Infections and infestations	52 (43.3)	13 (10.8)	45 (38.1)	13 (11.0)	27 (23.1)	6 (5.1)
Pneumonia	26 (21.7)	6 (5.0)	19 (16.1)	6 (5.1)	13 (11.1)	3 (2.6)

Abbreviations: PC, Paclitaxel+Carboplatin; T+PC, Tislelizumab+Paclitaxel+Carboplatin; T+nPC, Tislelizumab+nab-Paclitaxel+Carboplatin.

Adverse event Grades were evaluated based on NCI-CTCAE (version 5.0). Patients with multiple events for a given preferred term and system organ class were counted only once at the maximum Grade for the preferred term and system organ class, respectively.

Previously Treated Non-Small Cell Lung Cancer

The data described below reflect exposure to tislelizumab in 534 patients with locally advanced or metastatic NSCLC (squamous or non-squamous) in RATIONALE-303. Patients received 200 mg of tislelizumab via intravenous infusion every 3 weeks [see 5.1 Pharmacodynamic properties (Clinical trials)]. The median duration of exposure to tislelizumab was 23.3 weeks (range: 1 to 140 weeks).

The most common adverse events ($\geq 15\%$) were anaemia, decreased appetite, cough, weight decreased, alanine aminotransferase increased, and aspartate aminotransferase increase.

The most common \geq Grade 3 adverse events ($\geq 5\%$) were pneumonia.

Serious adverse events occurred in 32.6% of patients; the most frequent serious adverse events ($\geq 1\%$) were pneumonia, pneumonitis, immune-mediated pneumonitis, interstitial lung disease, haemoptysis, dyspnoea, and pleural effusion.

Fatal adverse events related to tislelizumab occurred in 1.5% of patients, including multiple organ dysfunction syndrome, pneumonitis, and hepatic function abnormal (1 patient each), death, respiratory failure, and pneumonia (2 patients each).

Adverse events leading to discontinuation of tislelizumab occurred in 10.5% of patients; the most common adverse events resulting in permanent discontinuation ($\geq 1\%$) were pneumonitis, interstitial lung disease and pneumonia.

Adverse events leading to the interruption of tislelizumab occurred in 22.3% of patients; the most common adverse events leading to interruption of tislelizumab ($\geq 2\%$) were pneumonia, and blood creatine phosphokinase increased.

Adverse events are listed in Table 8.

Table 8 Adverse Events ($\geq 10\%$) in Patients Receiving tislelizumab in RATIONALE-303

System Organ Class Preferred Term	Tislelizumab (N = 534)		Docetaxel (N = 258)	
	All Grades n (%)	\geq Grade 3 n (%)	All Grades n (%)	\geq Grade 3 n (%)
Investigations	311 (58.2)	40 (7.5)	174 (67.4)	82 (31.8)
Alanine aminotransferase increased	106 (19.9)	4 (0.7)	38 (14.7)	0 (0.0)
Aspartate aminotransferase increased	101 (18.9)	5 (0.9)	31 (12.0)	1 (0.4)
Weight decreased	81 (15.2)	4 (0.7)	26 (10.1)	0 (0.0)
White blood cell count decreased	20 (3.7)	1 (0.2)	74 (28.7)	47 (18.2)
Neutrophil count decreased	15 (2.8)	3 (0.6)	95 (36.8)	71 (27.5)
Respiratory, thoracic and mediastinal disorders	253 (47.4)	58 (10.9)	111 (43.0)	19 (7.4)
Cough	104 (19.5)	5 (0.9)	40 (15.5)	1 (0.4)
Dyspnoea	61 (11.4)	9 (1.7)	32 (12.4)	6 (2.3)
Haemoptysis	57 (10.7)	6 (1.1)	22 (8.5)	3 (1.2)
Metabolism and nutrition disorders	252 (47.2)	37 (6.9)	118 (45.7)	27 (10.5)
Decreased appetite	82 (15.4)	5 (0.9)	59 (22.9)	3 (1.2)
Hypoalbuminaemia	70 (13.1)	0 (0.0)	41 (15.9)	1 (0.4)
Hyperglycaemia	56 (10.5)	8 (1.5)	29 (11.2)	3 (1.2)
Hyponatraemia	49 (9.2)	8 (1.5)	29 (11.2)	11 (4.3)

System Organ Class Preferred Term	Tislelizumab (N = 534)		Docetaxel (N = 258)	
	All Grades n (%)	≥ Grade 3 n (%)	All Grades n (%)	≥ Grade 3 n (%)
General disorders and administration site conditions	215 (40.3)	24 (4.5)	132 (51.2)	28 (10.9)
Asthenia	67 (12.5)	6 (1.1)	56 (21.7)	14 (5.4)
Pyrexia	56 (10.5)	1 (0.2)	26 (10.1)	0 (0.0)
Gastrointestinal disorders	194 (36.3)	12 (2.2)	127 (49.2)	11 (4.3)
Constipation	65 (12.2)	0 (0.0)	42 (16.3)	0 (0.0)
Nausea	59 (11.0)	0 (0.0)	41 (15.9)	1 (0.4)
Diarrhoea	35 (6.6)	4 (0.7)	35 (13.6)	5 (1.9)
Blood and lymphatic system disorders	179 (33.5)	26 (4.9)	174 (67.4)	111 (43.0)
Anaemia	152 (28.5)	18 (3.4)	112 (43.4)	16 (6.2)
Leukopenia	15 (2.8)	1 (0.2)	69 (26.7)	41 (15.9)
Neutropenia	9 (1.7)	3 (0.6)	81 (31.4)	72 (27.9)
Febrile neutropenia	0 (0.0)	0 (0.0)	33 (12.8)	33 (12.8)
Infections and infestations	151 (28.3)	47 (8.8)	77 (29.8)	38 (14.7)
Pneumonia	61 (11.4)	38 (7.1)	36 (14.0)	24 (9.3)
Skin and subcutaneous tissue disorders	102 (19.1)	3 (0.6)	135 (52.3)	4 (1.6)
Alopecia	5 (0.9)	0 (0.0)	122 (47.3)	2 (0.8)
Endocrine disorders	79 (14.8)	3 (0.6)	2 (0.8)	0 (0.0)
Hypothyroidism	57 (10.7)	0 (0.0)	2 (0.8)	0 (0.0)

Adverse event Grades were evaluated based on NCI-CTCAE (version 4.03).

Patients with multiple events for a given preferred term and system organ class were counted only once at the maximum Grade for the preferred term and system organ class, respectively.

Gastric/Gastro-oesophageal Junction (G/GOJ) Adenocarcinoma

The data described below reflect exposure to tislelizumab in 498 patients with previously untreated locally advanced unresectable or metastatic gastric or gastro-oesophageal (G/GOJ) junction adenocarcinoma in RATIONALE-305. Patients received tislelizumab 200 mg plus platinum and fluoropyrimidine based chemotherapy (T+PtF arm) [see section 5.1 Pharmacodynamic properties (Clinical trials)]. The median duration of exposure to tislelizumab was 25.7 weeks (range: 0.4 to 204.4 weeks).

The most common adverse events (≥ 30%) were nausea, decreased appetite, anaemia, vomiting, platelet count decreased, neutrophil count decreased and aspartate aminotransferase increased.

The most common ≥ Grade 3 adverse events (≥ 5%) were neutropenia, neutrophil count decreased, platelet count decreased and anaemia.

Serious adverse events occurred in 42.4% of patients who received tislelizumab; the most frequent serious adverse events (≥ 2%) were platelet count decreased, pneumonia and death.

Fatal adverse events occurred in 9.4% of patients. Excluding cases where the primary reason for death was disease progression, death due to adverse event occurred in 4.2% of patients, including death, sepsis, pulmonary embolism, respiratory failure, colitis, pneumonia, pneumonia bacterial, respiratory tract infection viral, shock hemorrhagic, subdural hematoma and sudden death.

Adverse events leading to discontinuation of tislelizumab occurred in 15.7% of patients; the most common adverse events resulting in permanent discontinuation (≥ 1%) were death, peripheral sensory neuropathy, platelet count decreased and pneumonitis.

Adverse events leading to the treatment modification of tislelizumab occurred in 49.0% of patients; the most common adverse events leading to treatment modification of tislelizumab ($\geq 10\%$) were platelet count decreased, neutrophil count decreased and white blood cell count decreased.

Adverse events are listed in Table 9.

Table 9 Adverse Events ($\geq 10\%$) in Patients Receiving Tislelizumab in RATIONALE-305

System Organ Class Preferred Term	Tislelizumab (N = 534)		Docetaxel (N = 258)	
	All Grades n (%)	\geq Grade 3 n (%)	All Grades n (%)	\geq Grade 3 n (%)
Investigations	311 (58.2)	40 (7.5)	174 (67.4)	82 (31.8)
Alanine aminotransferase increased	106 (19.9)	4 (0.7)	38 (14.7)	0 (0.0)
Aspartate aminotransferase increased	101 (18.9)	5 (0.9)	31 (12.0)	1 (0.4)
Weight decreased	81 (15.2)	4 (0.7)	26 (10.1)	0 (0.0)
White blood cell count decreased	20 (3.7)	1 (0.2)	74 (28.7)	47 (18.2)
Neutrophil count decreased	15 (2.8)	3 (0.6)	95 (36.8)	71 (27.5)
Respiratory, thoracic and mediastinal disorders	253 (47.4)	58 (10.9)	111 (43.0)	19 (7.4)
Cough	104 (19.5)	5 (0.9)	40 (15.5)	1 (0.4)
Dyspnoea	61 (11.4)	9 (1.7)	32 (12.4)	6 (2.3)
Haemoptysis	57 (10.7)	6 (1.1)	22 (8.5)	3 (1.2)
Metabolism and nutrition disorders	252 (47.2)	37 (6.9)	118 (45.7)	27 (10.5)
Decreased appetite	82 (15.4)	5 (0.9)	59 (22.9)	3 (1.2)
Hypoalbuminaemia	70 (13.1)	0 (0.0)	41 (15.9)	1 (0.4)
Hyperglycaemia	56 (10.5)	8 (1.5)	29 (11.2)	3 (1.2)
Hyponatraemia	49 (9.2)	8 (1.5)	29 (11.2)	11 (4.3)
General disorders and administration site conditions	215 (40.3)	24 (4.5)	132 (51.2)	28 (10.9)
Asthenia	67 (12.5)	6 (1.1)	56 (21.7)	14 (5.4)
Pyrexia	56 (10.5)	1 (0.2)	26 (10.1)	0 (0.0)
Gastrointestinal disorders	194 (36.3)	12 (2.2)	127 (49.2)	11 (4.3)
Constipation	65 (12.2)	0 (0.0)	42 (16.3)	0 (0.0)
Nausea	59 (11.0)	0 (0.0)	41 (15.9)	1 (0.4)
Diarrhoea	35 (6.6)	4 (0.7)	35 (13.6)	5 (1.9)
Blood and lymphatic system disorders	179 (33.5)	26 (4.9)	174 (67.4)	111 (43.0)
Anaemia	152 (28.5)	18 (3.4)	112 (43.4)	16 (6.2)
Leukopenia	15 (2.8)	1 (0.2)	69 (26.7)	41 (15.9)
Neutropenia	9 (1.7)	3 (0.6)	81 (31.4)	72 (27.9)
Febrile neutropenia	0 (0.0)	0 (0.0)	33 (12.8)	33 (12.8)
Infections and infestations	151 (28.3)	47 (8.8)	77 (29.8)	38 (14.7)
Pneumonia	61 (11.4)	38 (7.1)	36 (14.0)	24 (9.3)
Skin and subcutaneous tissue disorders	102 (19.1)	3 (0.6)	135 (52.3)	4 (1.6)
Alopecia	5 (0.9)	0 (0.0)	122 (47.3)	2 (0.8)
Endocrine disorders	79 (14.8)	3 (0.6)	2 (0.8)	0 (0.0)
Hypothyroidism	57 (10.7)	0 (0.0)	2 (0.8)	0 (0.0)

Abbreviations: T+PtF = Tislelizumab + Platinum fluoropyrimidine based chemotherapy; P+PtF = Placebo + Platinum fluoropyrimidine based chemotherapy

Adverse event Grades were evaluated based on NCI-CTCAE (version 5.0). Patients with multiple events for a given preferred term and system organ class were counted only once at the maximum Grade for the preferred term and system organ class, respectively.

Laboratory abnormalities

Clinically relevant abnormalities of routine haematological or biochemical laboratory values from the data set of the 9 pooled studies of tislelizumab as monotherapy and the 9 pooled studies of tislelizumab in combination with chemotherapy are presented in Table 10.

Table 10 Laboratory abnormalities worsening from baseline with TEVIMBRA as monotherapy (N = 2,390) and in combination with chemotherapy (N = 1,950)

	Tislelizumab monotherapy N = 2,390	Tislelizumab combination therapy N = 1,950
Laboratory abnormality parameter*	All Grades n (%)	All Grades n (%)
Hematological parameters		
Haemoglobin increased	91 (3.9)	39 (2.1)
Haemoglobin decreased	905 (38.8)	1559 (82)
Leukocytes decreased	372 (16)	1454 (76.5)
Lymphocytes increased	44 (2)	38 (3.3)
Lymphocytes decreased	897 (40.8)	714 (61.5)
Neutrophils decreased	280 (12.7)	1499 (79.7)
Platelets decreased	361 (15.5)	1148 (60.4)
Biochemical parameters		
Alanine aminotransferase increased	741 (31.8)	794 (41.8)
Albumin decreased	799 (34.3)	887 (46.7)
Alkaline phosphatase increased	759 (32.6)	593 (31.3)
Aspartate aminotransferase increased	838 (36)	883 (46.5)
Bilirubin increased	502 (21.6)	500 (26.3)
Creatine kinase increased	259 (20.7)	433 (23.9)
Creatinine increased	333 (14.3)	420 (22.1)
Potassium increased	236 (10.2)	263 (13.8)
Potassium decreased	348 (15)	571 (30)
Sodium increased	142 (6.1)	127 (6.7)
Sodium decreased	763 (32.8)	1025 (53.9)

*Each test incidence is based on the number of patients who had both baseline and at least one post-baseline laboratory measurement available: Monotherapy (range: 1,254 to 1,914 patients), combination therapy (range: 1,161 to 1,901 patients).

Description of selected adverse drug reactions

Immune-related ADRs

The data below reflect information for ADRs for tislelizumab as monotherapy in clinical studies. Details for the ADRs for tislelizumab when given in combination are presented if clinically relevant differences were noted in comparison to tislelizumab monotherapy.

Immune-related pneumonitis

In patients treated with tislelizumab as monotherapy, immune-related pneumonitis occurred in 113 (4.7%) of 2,390 patients, including Grade 1 (25 patients, 1.0%), Grade 2 (46 patients, 1.9%), Grade 3 (33 patients, 1.4%), Grade 4 (6 patients, 0.3%) and Grade 5 (3 patients, 0.1%) events.

The median time from first dose to onset of the event was 3.9 months (range: 1.0 day to 55 months), and the median duration of the event was 6 months (range: 1+ day to 48.3+ months). + denotes a censored observation, with ongoing events at the time of the analysis. tislelizumab was permanently discontinued in 44 (1.8%) patients and tislelizumab treatment was interrupted in 40 (1.7%) patients.

Eighty-one (71.7%) of the 113 patients received systemic corticosteroids. + denotes a censored observation. 74 (65.5%) of the 113 patients received high-dose (defined as a dose \geq 40 mg/day of prednisone or equivalent) systemic corticosteroids. Two (1.8%) of 113 patients received immunosuppressive treatment. Pneumonitis resolved in 55 (48.7%) of the 113 patients.

Immune-related hepatitis

In patients treated with tislelizumab as monotherapy, immune-related hepatitis occurred in 30 (1.3%) of 2,390 patients, including Grade 1 (2 patients, 0.1%), Grade 2 (7 patients, 0.3%), Grade 3 (15 patients, 0.6%), and Grade 4 (4 patients, 0.3%) events.

The median time from first dose to onset of the event was 1.1 months (range: 14 days to 34.8 months), and the median duration of the event was 1.9 months (range: 6 days to 6.6 months). Tislelizumab was permanently discontinued in 6 (0.3%) patients and tislelizumab treatment was interrupted in 19 (0.8%) of patients for immune-related hepatitis.

Twenty-five (83.3%) out of 30 patients received systemic corticosteroids. Twenty-four (80%) of the 30 patients received high-dose systemic corticosteroids (defined as a dose \geq 40 mg/day of prednisone or equivalent). Two (6.7%) of the 30 patients received other immunosuppressive treatment. Hepatitis resolved in 20 (66.7%) of the 30 patients. The median duration for all resolved events was 27.5 days (range: 6 days to 6.6 months).

Immune-related skin adverse reactions

In patients treated with tislelizumab as monotherapy, immune-related skin adverse reactions occurred in 113 (13%) of 2,390 patients, including Grade 1 (201 patients, 8.4%), Grade 2 (82 patients, 3.4%), Grade 3 (26 patients, 1.1%) and Grade 4 (2 patients, 0.1%) events.

The median time from first dose to onset of the event was 1.5 months (range: 1 day to 36.1 months). The median duration of the event was 2.1 months (range: 1.0 day to 61.6+ months). + denotes a censored observation. tislelizumab was permanently discontinued in 3 (0.1%) patients, and tislelizumab treatment was interrupted in 30 (1.3%) patients.

Forty-four (14.1%) of the 311 patients received systemic corticosteroids. Nineteen (6.1%) of the 311 patients received high-dose systemic corticosteroids (defined as a dose \geq 40 mg/day of prednisone or equivalent). Two out of 311 patients (0.6%) received immunosuppressive treatment. Skin adverse reactions resolved in 208 (66.9%) of the 311 patients. The median duration for all resolved events was 32 days (range: 1 day to 36.7 months).

Immune-related colitis

In patients treated with tislelizumab as monotherapy, immune-related colitis occurred in 19 (0.8%) of 2,390 patients, including Grade 1 (1 patient, 0.04%), Grade 2 (10 patients, 0.4%) and Grade 3 (8 patients, 0.3%) events.

The median time from first dose to onset of the event was 6 months (range: 6 days to 26.5 months), and the median duration of the event was 26 days (range: 5 days to 26.7 months). Tislelizumab was permanently discontinued in 5 (0.2%) patients and tislelizumab treatment was interrupted in 10 (0.4%) patients.

Seventeen of the 19 patients received systemic corticosteroids. Twelve (63.2%) of the 19 patients were treated with high-dose systemic corticosteroids (defined as a dose \geq 40 mg/day of prednisone or equivalent). Two (10.5%) of the 19 patients received immunosuppressive treatment. Colitis resolved in 17 (89.5%) of the 19 patients. The median duration for all resolved events was 26 days (range: 5 days to 26.7 months).

Immune-related myositis/rhabdomyolysis

In patients treated with tislelizumab as monotherapy, immune-related myositis/rhabdomyolysis occurred in 17 (0.7%) of 2,390 patients, including Grade 1 (7 patients, 0.3%), Grade 2 (5 patients, 0.2%), Grade 3 (4 patients, 0.2%) and Grade 4 (1 patient, 0.04%) events.

The median time from first dose to onset of the event was 1.6 months (range: 15 days to 39.3 months), and the median duration of the event was 43 days (range: 5 days to 5.2 months). Tislelizumab was permanently discontinued in 4 (0.2%) patients and tislelizumab treatment was interrupted in 9 (0.4%) patients.

Nine (52.9%) of the 17 patients received systemic corticosteroids. Eight (47.1%) of the 17 patients were treated with high-dose systemic corticosteroids (defined as a dose \geq 40 mg/day of prednisone or equivalent). One (5.9%) out of the 17 patients received immunosuppressive treatment.

Myositis/rhabdomyolysis resolved in 13 (76.5%) of the 17 patients. The median duration for all resolved events was 40.5 days (range: 5 days to 5.2 months).

Immune-related endocrinopathies

Thyroid disorders

Hypothyroidism:

In patients treated with tislelizumab as monotherapy, hypothyroidism occurred in 299 (12.5%) of 2,390 patients, including Grade 1 (137 patients, 5.7%), Grade 2 (160 patients, 6.7%), Grade 3 (1 patient, 0.04%), and Grade 4 (1 patient, 0.04%) events.

The median time from first dose to onset of the event was 3.7 months (range: 1 day to 29.9 months). The median duration of the event was 10.3 months (range: 1+ day to 56+ months). + denotes a censored observation. Tislelizumab was permanently discontinued in 2 (0.1%) patients and tislelizumab treatment was interrupted in 12 (0.5%) patients. Two (0.7%) of the 299 patients received systemic corticosteroids. No patient received high-dose systemic corticosteroids. One hundred ninety-five patients received hormone replacement therapy. Hypothyroidism resolved in 103 (34.4%) of the 299 patients. The median duration for all resolved events was 2.1 months (range: 2 days to 27 months).

Hyperthyroidism:

In patients treated with tislelizumab as monotherapy, hyperthyroidism occurred in 118 (4.9%) of 2,390 patients, including Grade 1 (95 patients, 4.0%), Grade 2 (22 patients, 0.9%) and Grade 3 (1 patient, 0.04%) events.

The median time from first dose to onset of the event was 2.1 months (range: 6 days to 39.4 months). The median duration of the event was 2.1 months (range: 8 days to 48.4+ months). + denotes a censored observation. Tislelizumab was permanently discontinued in one (0.04%) patient and tislelizumab treatment was interrupted in 7 (0.3%) patients. Two (2.5%) of the 118 patients received systemic corticosteroids. One patient received high-dose systemic corticosteroids (defined as a dose \geq 40 mg/day of prednisone or equivalent). Nineteen (16.1%) of the 118 patients received hormone replacement therapy. Hyperthyroidism resolved in 90 (76.3%) of the 118 patients. The median duration for all resolved events was 1.4 months (range: 8 days to 22.1 months). Thyroiditis

In patients treated with tislelizumab as monotherapy, thyroiditis occurred in 25 (1.0%) of 2,390 patients, including Grade 1 (124 patients, 0.5%) and Grade 2 (13 patients, 0.5%) events.

The median time from first dose to onset of the event was 2.0 months (range: 14 days to 20.7 months). The median duration of the event was 7.3 months (range: 20 days to 34.5+ months). + denotes a censored observation. Tislelizumab was not permanently discontinued in any patient and tislelizumab treatment was interrupted in 5 (0.2%) patients.

Two (8%) of the 25 patients received systemic corticosteroids. No patients received high-dose systemic corticosteroids. Sixteen (64%) of the 25 patients received hormone replacement therapy. Thyroiditis resolved in 9 (36%) of the 25 patients. The median duration for all resolved events was 2 months (range: 20 days to 15.3 months).

Adrenal insufficiency

In patients treated with tislelizumab as monotherapy, adrenal insufficiency occurred in 12 (0.5%) of 2,390 patients, including Grade 2 (7 patients, 0.3%), Grade 3 (4 patients, 0.2%) and Grade 4 (1 patient, 0.04%) events.

The median time from first dose to onset of the event was 9.7 months (range: 1.4 months to 16.9 months). The median duration of the event was not reached (range: 1 month to 27.9+ months). + denotes a censored observation. Tislelizumab was not permanently discontinued in any patient and tislelizumab treatment was interrupted in 10 (0.4%) patients. All 12 patients received systemic corticosteroids. Three (25%) of the 12 patients received high-dose systemic corticosteroids (defined as a dose ≥ 40 mg/day of prednisone or equivalent). Adrenal insufficiency resolved in 3 (25%) of the 12 patients. The median duration for all resolved events was 1.9 months (range: 30 days to 13.6 months).

Hypophysitis

In patients treated with tislelizumab as monotherapy, hypophysitis occurred in 6 (0.3%) of 2,390 patients, all Grade 2.

The median time from first dose to onset of the event was 8.7 months (range: 22 days to 16.2 months). The median duration of the event was not reached (range: 70 days to 30+ months). + denotes a censored observation. Tislelizumab was not permanently discontinued in any patients and treatment was interrupted in 1 (0.04%) patient.

Five (83.3%) of the 6 patients received systemic corticosteroids. One (16.7%) of the 6 patients received high-dose systemic corticosteroids (defined as a dose ≥ 40 mg/day of prednisone or equivalent). Hypophysitis resolved in 1 (16.7%) of the 6 patients. The duration for the resolved event was 2.3 months.

Diabetes mellitus In patients treated with tislelizumab as monotherapy, diabetes mellitus occurred in 16 (0.7%) patients, including Grade 1 (1 patient, 0.04%), Grade 2 (6 patients, 0.3%), Grade 3 (6 patients, 0.3%) and Grade 4 (3 patients, 0.1%) events.

The median time from first dose to onset of the event was 6.5 months (range: 22 days to 36.1 months). The median duration of the event was not reached (range: 2 days to 44.5+ months). + denotes a censored observation. Tislelizumab was permanently discontinued in 4 (0.2%) patients and tislelizumab treatment was interrupted in 4 (0.2%) of patients.

Diabetes mellitus resolved in 2 (12.5%) of 16 patients. The median duration for all resolved events was 22 days (range: 2 days to 3.6 months). Fourteen (87.5%) of the 16 patients received insulin therapy for diabetes mellitus.

Immune-related nephritis and renal dysfunction

In patients treated with tislelizumab as monotherapy, immune-related nephritis and renal dysfunction occurred in 5 (0.2%) of 2,390 patients, including Grade 1 (1 patient, 0.04%), Grade 2 (3 patients, 0.1%), and Grade 3 (1 patient, 0.04%) events.

The median time from first dose to onset of the event was 2.1 months (range: 15 days to 34.5 months). The median duration of the event was not reached (range: 9 days to 16.2+ months). + denotes a censored observation. Tislelizumab was permanently discontinued in 1 (0.04%) patient and tislelizumab treatment was interrupted in 3 (0.1%) patients.

Three (60%) out of 5 patients received systemic corticosteroids. All 3 patients received high-dose systemic corticosteroids (defined as a dose ≥ 40 mg/day of prednisone or equivalent). One (20%) of the 5 patients received immunosuppressive treatment. Immune-related nephritis and renal dysfunction resolved in 2 (40%) of the 5 patients. The duration for all resolved events was 9 days.

Immune-related myocarditis

In patients treated with tislelizumab as monotherapy, immune-related myocarditis occurred in 15 (0.6%) of 2,390 patients, including Grade 1 (8 patients, 0.3%), Grade 2 (3 patients, 0.1%), Grade 3 (3 patients, 0.1%) and Grade 4 (1 patient, 0.04%) events.

The median time from first dose to onset of the event was 1.6 months (range: 14 days to 33.6 months), and the median duration of the event was 5.1 months (range: 4 days to 26.4+ months). + denotes a censored observation. Tislelizumab was permanently discontinued in 7 (0.3%) patients and tislelizumab treatment was interrupted in 8 (0.3%) patients.

Ten (66.7%) of the 15 patients received systemic corticosteroids, with a median initial dose of 75 mg/day (range: 20 to 200 mg/day) for a median duration of 28.5 days (range: 1.0 day to 2.4+ months). + denotes a censored observation. Nine (60%) of the 15 patients received high-dose corticosteroids (defined as a dose ≥ 40 mg/day of prednisone or equivalent). One (6.7%) of the 15 patients received immunosuppressive treatment. Myocarditis resolved in 9 (60%) of the 15 patients. The median duration for all resolved events was 1.2 months (range: 4 days to 15.6 months).

Infusion related reactions

In patients treated with tislelizumab as monotherapy, infusion-related reactions occurred in 113 (4.7%) of 2,390 patients, including Grade 1 (74 patients, 3.1%), Grade 2 (36 patients, 1.5%), Grade 3 (2 patients, 0.1%) and Grade 4 (1 patient, 0.04%) events.

Twenty-three (20.4%) of the 113 patients received treatment with corticosteroids. Tislelizumab was permanently discontinued in 4 (0.2%) patients, and tislelizumab treatment was interrupted in 17 (0.7%) patients. Cases of anaphylaxis, including anaphylactic reaction and anaphylactic shock, have been reported in the post-marketing setting.

Immunogenicity

Overall, a 20.8% incidence (839 of 4035 anti-drug antibody (ADA) evaluable patients) of treatment-emergent ADA was observed following tislelizumab administration across all dose levels, including 0.5 to 10 mg/kg once every 2 weeks, 2 to 5 mg/kg once every 3 weeks, and 200 mg once every 3 weeks (including 200 mg once every 3 weeks in neoadjuvant phase followed by 400 mg once every 6 weeks in adjuvant phase). Neutralising antibodies were detected in 45 of these 4035 patients (1.1%).

Of 3,674 antidrug antibodies (ADA)-evaluable patients treated at the recommended dose of 200 mg once every 3 weeks with tislelizumab as monotherapy or in combination with chemotherapies, 776

(21.1%) of patients tested positive for treatment-emergent ADAs, the incidence of treatment-emergent ADA was 16.8% (307 of 1822 patients) for monotherapy and 25.3% (469 of 1852 patients) for combination therapy. Neutralising antibodies (NAbs) were detected in 45 (1.2%) of patients. The incidence of neutralising antibodies was 1.3% (23 of 1822 patients) for monotherapy and 1.2% (22 of 1852 patients) for combination therapy. Population pharmacokinetic analysis showed that ADA status was a statistically significant covariate on clearance, however, the presence of treatment-emergent ADA against tislelizumab appears to have no clinically relevant impact on pharmacokinetics, efficacy, or safety.

Elderly

No overall differences in safety were observed with tislelizumab monotherapy between patients aged <65 years and patients aged between 65 and 74 years. Data for patients aged ≥ 75 years are too limited to draw conclusions on this population.

Immune checkpoint inhibitor class effects

There have been cases of the following adverse reactions reported during treatment with other immune checkpoint inhibitors which might also occur during treatment with tislelizumab: pancreatic exocrine insufficiency, aplastic anaemia.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicine is important. It allows continued monitoring of the benefit/risk balance of the medicine. Healthcare professionals are asked to report any suspected adverse reactions at <https://pophealth.my.site.com/carmreportnz/s/>.

4.9 OVERDOSE

There is no information on overdose with tislelizumab. No cases of overdose have been reported in clinical trials. In case of overdose, patients should be closely monitored for signs or symptoms of adverse drug reactions, and appropriate symptomatic treatment instituted immediately.

For risk assessment and advice on the management of overdose please contact the National Poisons Centre on 0800 POISON (0800 764766).

5 PHARMACOLOGICAL PROPERTIES

5.1 PHARMACODYNAMIC PROPERTIES

Pharmacotherapeutic group: Antineoplastic agents, monoclonal antibodies. ATC code: L01FF09.

Mechanism of action

Binding of the PD-1 ligands PD-L1 and PD-L2, to the PD-1 receptor found on T-cells, inhibits T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumours and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumours.

Tislelizumab is a humanized immunoglobulin G4 (IgG4) variant monoclonal antibody against PD-1, binding to the extracellular domain of human PD-1 with high specificity and affinity ($KD = 0.15$ nM). It competitively blocks the binding of both PD-L1 and PD-L2, inhibiting PD-1-mediated negative signaling and enhancing the functional activity in T-cells in *in vitro* cell-based assays. In *in vitro* studies, tislelizumab did not bind to Fc gamma receptors (Fc γ Rs) and *C1q*, and therefore did not induce antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity

(CDC); it is not expected to induce antibody dependent cellular phagocytosis (ADCP). Tislelizumab demonstrated decreased tumour growth in several human cancer allogeneic xenograft models and a human PD-1 transgenic mouse model.

Clinical trials

Oesophageal squamous cell carcinoma (OSCC)

First-line treatment of unresectable, locally advanced, recurrent, locally advanced or metastatic OSCC in combination with chemotherapy

BGB-A317-306 is a randomised, double-blind placebo-controlled, global phase III study to compare the efficacy of tislelizumab in combination with platinum-based chemotherapy versus placebo in combination with platinum-based chemotherapy in patients with unresectable, locally advanced recurrent or metastatic OSCC.

The study enrolled patients who were not amenable to chemoradiation or surgery with curative intent. Patients were enrolled regardless of their tumour PD-L1 expression level. Where available, the archival/fresh tumour tissue specimens taken were retrospectively tested for PD-L1 expression status. PD-L1 expression was evaluated using TAP (tumour area positivity) score, defined as the total percentage of the tumour area (tumour and any desmoplastic stroma) covered by tumour cells with PD-L1 membrane staining at any intensity and tumour-associated immune cells with PD-L1 staining at any intensity, as visually estimated using the VENTANA PD-L1 (SP263) Assay. Patients who had received prior systemic therapy for advanced or metastatic disease were excluded. A treatment-free interval of at least 6 months was required if the patient had received prior neoadjuvant/adjuvant therapy with platinum-based chemotherapy.

The study excluded patients who had evidence of fistula or complete oesophageal obstruction not amenable to treatment.

Randomisation was stratified by geographical region (Asia [excluding Japan] versus Japan versus rest of world [ROW]), prior definitive therapy (yes versus no) and investigator choice of chemotherapy (ICC; platinum with fluoropyrimidine or platinum with paclitaxel).

Patients were randomised (1:1) to receive either tislelizumab 200 mg or placebo every 3 weeks in combination with investigator's choice of chemotherapy (ICC) on a 21-day cycle. The chemotherapy doublet regimen consisted of:

- platinum (cisplatin [60 to 80 mg/m² IV on day 1] or oxaliplatin [130 mg/m² IV on day 1]) and a fluoropyrimidine (5-FU [750 to 800 mg/m² IV on days 1 to 5] or capecitabine [1000 mg/m² orally twice daily on days 1 to 14]), or
- platinum (cisplatin [60 to 80 mg/m² IV on day 1 or 2] or oxaliplatin [130 mg/m² IV on day 1 or 2]) and paclitaxel (175 mg/m² IV on day 1).

Patients were treated with tislelizumab in combination with chemotherapy or placebo in combination with chemotherapy until disease progression, as assessed by the investigator per RECIST version 1.1 or unacceptable toxicity. After 24 months of treatment, study therapy could be continued beyond two years if the investigator considered this to be in the best interest of the patient based on an assessment of clinical benefit and potential risks.

The tumour assessments were conducted every 6 weeks for the first 48 weeks, and every 9 weeks thereafter.

The primary efficacy endpoint was overall survival (OS) in the intent-to-treat (ITT) population. Secondary efficacy endpoints were progression-free survival (PFS), objective response rate (ORR)

and duration of response (DoR) as assessed by the investigator per RECIST v1.1, OS in the PD-L1 positive (PD-L1 score $\geq 10\%$) subgroup and health-related quality of life (HRQoL).

A total of 649 patients were randomised to receive tislelizumab in combination with chemotherapy (n = 326) or placebo in combination with chemotherapy (n = 323). Of the 649 patients, 293 (45.1%) patients were randomised to receive platinum + fluoropyrimidine, 481 (74.1%) patients had PD-L1 score $\geq 1\%$, 61 (9.4%) patients had PD-L1 score $< 1\%$ and 107 (16.5%) patients had PD-L1 status unknown.

In patients with a PD-L1 score $\geq 1\%$, the baseline characteristics were: median age 64 years (range: 38 to 84), 47.2% age 65 years or older; 86.3% male; 22.9% White and 75.9% Asian. 86.9% had metastatic disease at study entry and 13.1% had locally advanced disease. All patients had histological confirmation of squamous cell carcinoma. Baseline ECOG performance status was 0 (33.9%) or 1 (66.1%).

BGB-A317-306 showed a statistically significant improvement in OS for patients randomised to tislelizumab in combination with chemotherapy as compared to placebo in combination with chemotherapy. As of the interim analysis (data cut-off (DCO): 28 February 2022), in patients with a PD-L1 score $\geq 1\%$, the OS HR was 0.64 (95% CI: 0.51, 0.80, 1-sided p-value of < 0.0001), with a median OS of 16.8 months (95% CI: 15.3, 20.8) for the tislelizumab with chemotherapy arm vs. 9.6 months (95% CI: 8.9, 11.8) for the placebo with chemotherapy arm. The median follow-up times by reverse Kaplan-Meier methodology were 22.8 months in the tislelizumab in combination with chemotherapy arm and 23.3 months in the placebo in combination with chemotherapy arm.

An updated analysis (up to 3-year follow-up; DCO: 24 November 2023) with additional 20.8 months follow-up after the interim analysis showed consistent efficacy results with the interim analysis. The median follow-up times by reverse Kaplan-Meier methodology were 44.2 months in the tislelizumab in combination with chemotherapy arm and 43.8 months in the placebo in combination with chemotherapy arm.

Efficacy results for patients with PD-L1 score $\geq 1\%$, at 3-year follow-up, are shown in Table 11 and Figure 1.

Table 11 Efficacy results in BGB-A317-306 patients with PD-L1 score $\geq 1\%$ - 3-year follow-up (data cut-off 24 November 2023)

Endpoint	Tislelizumab + chemotherapy (N = 231)	Placebo + chemotherapy (N = 250)
OS		
Deaths, n (%)	178 (77.1)	207 (82.8)
Median (months) (95% CI)	16.8 (15.3, 20.8)	9.6 (8.9, 11.8)
HR (95% CI) ^a	0.66 (0.54, 0.81)	
p-value ^b	< 0.0001	
PFS		
Events, n (%)	164 (71.0)	205 (82.0)
Median (months) (95% CI)	7.2 (6.8, 8.5)	5.5 (4.5, 5.8)
HR (95% CI) ^a	0.54 (0.44, 0.67)	
p-value ^b	< 0.0001	
ORR^c		

Patient reported outcomes/Quality of life

Patient-reported outcomes (PROs) were collected using EORTC QLQ-C30, EORTC QLQ-OES18 and EQ-5D-5L questionnaires. Adjusted completion rate from baseline through Cycle 6 and Cycle 8 was $\geq 93\%$ and $\geq 91\%$, respectively, for each questionnaire in both treatment arms.

No significant differences between treatment arms were observed in the predefined PRO endpoints from baseline to the key clinical Cycle 6. The global health status/QoL and disease-specific symptoms (dysphagia, eating difficulties and reflux) did not worsen with the addition of tislelizumab to chemotherapy treatment, compared with those receiving placebo plus chemotherapy.

Risk of experiencing deterioration for GHS/QoL (HR 0.98 [95% CI 0.74, 1.29]), physical functioning (0.79 [0.60, 1.04]), dysphagia 0.92 (0.70, 1.20), eating 1.00 (0.72, 1.39) and reflux 1.15 (0.83, 1.60) subscales was similar between the treatment groups.

Second-line treatment of unresectable, recurrent, locally advanced or metastatic OSCC

RATIONALE-302 was a randomised, controlled, open-label, global phase III study to compare the efficacy of tislelizumab versus chemotherapy in patients with unresectable, recurrent, locally advanced or metastatic OSCC who progressed on or after prior systemic treatment. Patients were enrolled regardless of their tumour PD-L1 expression level. Where available, the archival/fresh tumour tissue specimens taken were retrospectively tested for PD-L1 expression status. Patients with inactive or asymptomatic carrier chronic or active HBV status and patients with detectable HCV receiving antivirals at screening were also enrolled in the study. The study excluded patients with active brain or leptomeningeal tumour invasion into organs located adjacent to the oesophageal disease site (e.g., aorta or respiratory tract), those who had received a prior immune checkpoint inhibitor, active autoimmune disease or history of autoimmune diseases, or any condition requiring systemic treatment with either corticosteroids or other immunosuppressive treatments. PD-L1 expression was evaluated at a central laboratory using the Ventana PD-L1 (SP263) assay that identified PD-L1 staining on both tumour and tumour-associated immune cells.

Patients were randomized (1:1) to receive tislelizumab 200 mg every 3 weeks or investigator's choice of chemotherapy (ICC), selected from the following, all given intravenously:

- paclitaxel 135 to 175 mg/m² on day 1, given every 3 weeks (also at doses of 80 to 100 mg/m² on a weekly schedule according to local and/or country-specific guidelines for standard of care, also administered as 100 mg/m² on Days 1, 8, 15, 22, 29, and 36, followed by 1 week of rest in Japan),
- docetaxel 75 mg/m² on day 1, given every 3 weeks (70 mg/m² on Day 1, given every 21 days in Japan), or
- irinotecan 125 mg/m² on days 1 and 8, given every 3 weeks.

Crossover between the tislelizumab arm and ICC arm was not permitted. In the ICC arm, switching between the different chemotherapy options was not permitted.

Randomization was stratified by geographic region (Asia [excluding Japan] versus Japan versus USA/EU), ECOG PS score (0 versus 1), and ICC option (paclitaxel versus docetaxel versus irinotecan). The choice of ICC was determined by the investigator before randomization.

Patients were treated with tislelizumab or one of the ICC until disease progression or unacceptable toxicity.

The tumour assessments were conducted every 6 weeks for the first 6 months, and every 9 weeks thereafter. Treatment beyond initial investigator-assessed progression was permitted in patients receiving tislelizumab with no rapid progression, investigator-assessed benefit, tolerance to treatment, stable performance status, and for whom treatment beyond progression would not delay an imminent

intervention to prevent serious complications associated with disease progression (e.g., brain metastasis).

The primary efficacy outcome measure was overall survival (OS) in the intent-to-treat (ITT) population. Key secondary efficacy outcome measure was OS in PD-L1 Positive Analysis Set (PD-L1 score $\geq 10\%$).

Additional secondary efficacy endpoints included objective response rate (ORR), progression-free survival (PFS) and duration of response (DoR), as assessed by the investigator per RECIST v 1.1 and health related quality of life.

A total of 512 patients were enrolled and randomized to tislelizumab (n=256) or ICC (n=256: paclitaxel (n=85), docetaxel (n=53), or irinotecan (n=118)). Of the 512 patients, 142 (27.7%) had PD-L1 score $\geq 10\%$, 222 (43.4%) had PD-L1 score $< 10\%$, and 148 (28.9%) had unknown baseline PD-L1 status.

The baseline characteristics for the 512 patients were: median age of 62 years (range: 35 to 86 years), 37.9% with 65 years of age or older; 84% male; 19% White and 80% Asian; 25% with an eastern cooperative oncology group performance status (ECOG PS) of 0 and 75% with an ECOG PS of 1. Ninety-five percent of the study population had metastatic disease at study entry. All patients had received at least one prior anti-cancer systemic therapy, which was a platinum-based chemotherapy for 97% of patients.

RATIONALE-302 demonstrated a statistically significant improvement in OS for patients randomized to tislelizumab arm as compared with the ICC arm. The median follow-up times by reverse Kaplan-Meier methodology were 20.8 months in the tislelizumab arm and 21.1 months in the ICC arm. Efficacy results are shown in Table 12 and Figure 2.

Table 12 Efficacy results in RATIONALE-302 (ITT analysis set)

Endpoint	Tislelizumab (N = 256)	Chemotherapy (N = 256)
OS		
Deaths n (%)	197 (77.0)	213 (83.2)
Median (months) ^a (95% CI)	8.6 (7.5, 10.4)	6.3 (5.3, 7.0)
Hazard ratio (95% CI) ^b	0.70 (0.57, 0.85)	
p-value ^c	p = 0.0001	
PFS		
Disease progression or death, n (%)	223 (87.1)	180 (70.3)
Median (months) (95% CI)	1.6 (1.4, 2.7)	2.1 (1.5, 2.7)
Hazard ratio (95% CI)	0.83 (0.67, 1.01)	
ORR with confirmation by investigator		
ORR, n	39	17
ORR (%) (95% CI)	15.2 (11.1, 20.2)	6.6 (3.9, 10.4)
CR, n (%)	5 (2.0)	1 (0.4)
PR, n (%)	34 (13.3)	16 (6.3)
SD, n (%)	81 (31.6)	90 (35.2)
Median DoR with confirmation by investigator (months) (95% CI)	10.3 (6.5, 13.2)	6.3 (2.8, 8.5)

Abbreviations: OS = overall survival; CI = confidence interval; PFS = progression-free survival; ORR = objective response rate; CR = complete response; PR = partial response; SD = stable disease; DoR = duration of response.


Endpoint	Tislelizumab (N = 256)	Chemotherapy (N = 256)
----------	---------------------------	---------------------------

^a Estimated using Kaplan-Meier method.

^b Based on Cox regression model including treatment as covariate and stratified by baseline ECOG status and investigator's choice of chemotherapy.

^c Based on a log rank test stratified by ECOG performance status and investigator's choice of chemotherapy.

Figure 2 Kaplan-Meier plot of OS in RATIONALE-302 (ITT analysis set)



Number of Patients at Risk:

Time:	0	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16	17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32
Tislelizumab	256	245	226	214	191	172	157	144	134	122	110	96	88	81	73	63	59	52	44	35	30	25	20	18	13	11	8	8	8	3	2	1	0
ICC	256	235	219	191	167	143	124	105	93	83	77	59	51	42	36	34	29	26	21	19	15	11	7	6	5	4	4	2	2	1	1	0	0

One-sided p-value was estimated from log-rank test stratified on ECOG status and ICC option. Hazard ratio was based on Cox regression model including treatment as covariate stratified by ECOG status and ICC option

Overall survival benefit with tislelizumab over ICC was consistent across subgroups, including age, gender, investigators choice of chemotherapy options (paclitaxel, docetaxel and irinotecan), smoking status, ECOG performance status, region (Asia versus America/Europe), baseline PD-L1 status, and race (Asian versus White).

PD-L1 subgroups

Of the 512 patients, 142 (27.7%) had PD-L1 positive OSCC, defined as PD-L1 score $\geq 10\%$. The remaining 222 (43.4%) had PD-L1 negative OSCC defined as PD-L1 score $< 10\%$ and 148 (28.9%) had baseline PD-L1 status missing.

In a pre-specified analysis of OS in the PD-L1 positive sub-group (PD-L1 score $\geq 10\%$), the stratified hazard ratio (HR) for OS was 0.49 (95% CI: 0.33 to 0.74), with a 1-sided stratified log-rank test p-value of 0.0003. The median survival was 10.0 months (95% CI: 8.5 to 15.1 months) and 5.1 months (95% CI: 3.8 to 8.2 months) for the tislelizumab and ICC arms, respectively.

In the PD-L1 negative subgroup (PD-L1 score $< 10\%$), the stratified HR for OS was 0.83 (95% CI: 0.62 to 1.12), with median overall survival of 7.5 months (95% CI: 5.5 to 8.9 months) and 5.8 months (95% CI: 4.8 to 6.9 months) for the tislelizumab arm and ICC arms, respectively.

Non-small cell lung cancer

First-line treatment of metastatic non-squamous NSCLC in combination with pemetrexed and platinum chemotherapy

The efficacy of tislelizumab was evaluated in RATIONALE-304 (NCT03663205), a multicenter, randomized, open-label, phase 3 study evaluating the efficacy and safety of tislelizumab combined with chemotherapy in untreated locally advanced non-squamous NSCLC patients who were not candidates for surgical resection or platinum based chemoradiation, or metastatic non-squamous NSCLC patients.

The study excluded patients with active brain or leptomeningeal metastases; with known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, active autoimmune disease, or any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive treatments.

A total of 334 patients were randomized (2:1) to receive tislelizumab 200 mg combined with pemetrexed 500 mg/m² and carboplatin AUC 5 mg/mL/min or cisplatin 75 mg/m² (T+PP arm, N = 223), or pemetrexed 500 mg/m² and carboplatin AUC 5 mg/mL/min or cisplatin 75 mg/m² (PP arm, N = 111). The choice of platinum (cisplatin or carboplatin) was at the investigator's discretion.

The treatment was administered on a 3-week cycle. After the administration of 4, 5, or 6 cycles of chemotherapy or tislelizumab combined with chemotherapy at the investigator's discretion, patients in arm T+PP received tislelizumab 200 mg combined with pemetrexed 500 mg/m² on a 3-week cycle until disease progression or unacceptable toxicity. Tislelizumab monotherapy was continued beyond disease progression if the patient was deriving clinical benefit as assessed by the investigator; patients in arm PP received pemetrexed 500 mg/m² alone until disease progression is confirmed or unacceptable toxicity, and those with disease progression confirmed by IRC given the option to cross over to receive tislelizumab monotherapy on a 3-week cycle.

Randomization was stratified by PD-L1 expression in tumour cells (TC) (<1% vs 1% to 49% vs ≥50%) and disease stage (IIIB vs IV), as classified according to American Joint Committee on Cancer (AJCC), 7th edition of Cancer Staging Manual. PD-L1 expression was evaluated at a central laboratory using the Ventana PD-L1 (SP263) assay that identified PD-L1 staining on tumour cells. Tumour assessments were conducted every 6 weeks for the first 6 months, then every 9 weeks for the second 6 months, then every 12 weeks.

The baseline characteristics for the study population were: median age of 61 years (range: 25 to 75 years), 29% with 65 years of age or older; 74% male; 100% Asian; 23.4% had an ECOG PS of 0 and 76.6% had an ECOG PS of 1; 18.3% had disease stage IIIB; 26.6% of the patients were unknown status on ALK rearrangement whereas 73.4% with negative ALK rearrangement; 36.2% of the patients were never-smokers; 5.4% with brain metastases, 4.6% PD-L1 TC score < 1%, 24.0% with PD-L1 TC score ≥1% and ≤49%, 32.9% with PD-L1 TC score ≥50%. The characteristics of age, sex, ECOG PS, stage, smoking status, PD-L1 expression and prior anticancer treatments were well balanced.

The primary efficacy endpoint was progression-free survival (PFS) per RECIST v.1.1 per IRC in the intent to treat (ITT) analysis. The secondary endpoints included overall survival (OS), PFS per investigator, objective response rate (ORR) and duration of response (DoR) per IRC and per investigator.

The study met its primary endpoint at the interim analysis (data cut-off date of 23-Jan 2020 and a median duration of study follow-up of 9.0 months) showing a statistically significant improvement in PFS with tislelizumab in combination with PP as compared with PP. The hazard ratio (HR) was 0.65 (95% CI: 0.47, 0.91; p = 0.0054) indicating a 35% reduction in the risk of experiencing disease progression or death, with a median PFS of 9.7 months with tislelizumab in combination with PP and 7.6 months with PP.

The final analysis (data cut-off date of 26-Oct-2020 and a median duration of study follow-up of 16.1 months) confirmed the results from the interim analysis. Efficacy results in the final analysis are shown in Table 13 and Figure 3.

Table 13 Efficacy results in RATIONALE-304 by IRC

Endpoint	Tislelizumab + Pemetrexed + Platinum (N = 223)	Pemetrexed + Platinum (N = 111)
PFS		
Events, n (%)	133 (59.6)	68 (61.3)
Median PFS (months) (95% CI)	9.8 (8.94, 11.70)	7.6 (5.55, 8.02)
Stratified Hazard Ratio ^{a,b} (95% CI)	0.63 (0.47, 0.86)	
Event-free rate		
12 months (%), (95% CI)	39.9 (32.8, 46.8)	20.1 (11.6, 30.2)
18 months (%), (95% CI)	26.6 (19.5, 34.3)	11.3 (4.6, 21.1)
OS		
Deaths n (%)	96 (43.0)	46 (41.4)
Median OS (months) (95% CI)	21.4 (17.68, NE)	21.3 (15.08, NE)
Stratified Hazard ratio (95% CI)	0.90 (0.63, 1.28)	
Event-free rate ^c (%), (95% CI)		
12 months ^c	76.4 (70.2, 81.5)	69.4 (59.4, 77.4)
18 months	55.4 (48.0, 62.2)	55.3 (44.6, 64.8)
Best Overall Response, n (%) ^d		
ORR, n (%) ^d	113 (50.7)	31 (27.9)
95% CI ^e	(43.9, 57.4)	(19.8, 37.2)
CR, n (%)	9 (4.0)	2 (1.8)
PR, n (%)	104 (46.6)	29 (26.1)
DoR ^d		
Median DoR (months) (95% CI)	14.5 (10.09, NE)	8.4 (5.95, 15.47)
Event-free rate		
6-months (%), (95% CI) ^f	78.5 (69.47, 85.19)	63.8 (41.78, 79.35)
12-months (%), (95% CI) ^f	53.9 (43.63, 63.11)	37.2 (18.32, 56.24)
18-months (%), (95% CI) ^f	42.0 (30.35, 53.17)	20.7 (4.86, 43.97)

Abbreviations: PFS = progression-free survival; CI = confidence interval; ORR = objective response rate; CR = complete response; PR = partial response; DoR = duration of response; NE = not estimable.

Medians were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

^a Stratified by stratification factors: disease stage (IIIB versus IV) and PD-L1 expression in tumour cell ($\geq 50\%$ versus 1%-49% versus $< 1\%$).

^b Hazard ratio was estimated from stratified Cox model with pemetrexed + platinum group as reference group.

^c The median time from randomization to crossover was 35.1 weeks and from end of study treatment to crossover is 2.6 weeks.


^d Confirmed response by independent review committee.

Endpoint	Tislelizumab + Pemetrexed + Platinum (N = 223)	Pemetrexed + Platinum (N = 111)
----------	--	------------------------------------

^e 95% CI was calculated using Clopper-Pearson method

^f Event free rates were estimated by Kaplan-Meier method with 95% CI evaluated using Greenwood's formula.

Figure 3 Kaplan-Meier plot of PFS in RATIONALE-304 by IRC



Abbreviations: CI = Confidence Interval; T+PP = Tislelizumab + Pemetrexed + Platinum; PP = Pemetrexed + Platinum.

Subgroup analyses demonstrated a consistently beneficial PFS treatment effect for Arm T+PP over Arm PP irrespective of tumour stage, and across major demographic and prognostic subgroups.

The benefit for PFS was observed in both PD-L1 TC score <1% (HR=0.83, 95% CI: 0.53, 1.28) and PD-L1 TC score ≥1% (HR=0.48, 95% CI: 0.32, 0.72). Within the PD-L1 positive group, the results from both PD-L1 TC score 1% to 49% subgroup (HR=0.90, 95% CI: 0.49, 1.63) and PD-L1 TC score ≥50% subgroup (HR=0.29, 95% CI: 0.16, 0.50) need to be interpreted with caution considering the small sample size. In addition, generally consistent treatment effect was observed for disease stages IIIB and IV.

In addition, generally consistent treatment benefit was observed for Arm T+PP over Arm PP for disease stages, with PFS HR of 0.63 (95% CI, HR = 0.31, 1.26) for stage IIIB and PFS HR of 0.59 (95% CI, 0.42, 0.82) for stage IV.

Table 14 Efficacy results of PFS by tumour PD-L1 expression in RATIONALE-304

	T +PP arm	PP arm
	N = 223	N = 111
PD-L1 expression in tumour cell <1%, n	91	48
Events, n (%)	64 (70.3)	30 (62.5)
Median PFS (months), (95% CI)	7.6 (5.0, 9.7)	7.6 (4.3, 7.9)
Hazard ratio (95% CI)	0.83 (0.53, 1.28)	
PD-L1 expression in tumour cell ≥1%, n	127	63
Events, n (%)	66 (52.0)	38 (60.3)
Median PFS (months), (95% CI)	11.9 (9.9, 17.3)	7.4 (4.5, 9.8)
Hazard ratio (95% CI)	0.48 (0.32, 0.72)	

	T +PP arm	PP arm
	N = 223	N = 111
PD-L1 expression in tumour cell 1%-49%, n	53	27
Events, n (%)	33 (62.3)	16 (59.3)
Median PFS (months)	9.7 (6.9, 11.7)	9.7 (5.6, 16.8)
Hazard ratio (95% CI)	0.90 (0.49, 1.63)	
PD-L1 expression in tumour cell ≥50%, n	74	36
Events, n (%)	33 (44.6)	22 (61.1)
Median PFS (months)	14.6 (11.5, NE)	4.6 (3.5, 9.7)
Hazard ratio ^a (95% CI)	0.29 (0.16, 0.50)	

^a Hazard ratio and its 95% CI was estimated from unstratified Cox model

Patient reported outcomes/Quality of life

Patient-reported outcomes (PROs) were collected using EORTC-QLQ-C30 and QLQ-LC13 questionnaires. QLQ-C30 and QLQ-LC13 completion rates among all treatment arms were 100% at baseline and remained ≥95% up to end of cycle 7.

The addition of tislelizumab to platinum-pemetrexed trended towards improvements in health-related quality of life (HRQoL) compared to platinum-pemetrexed alone in patients with previously untreated stage IIIB or IV non-squamous NSCLC. The median TTD (time to deterioration) for QLQ-C30 GHS/QoL was not reached in either treatment arms; the median TTD for the composite of cough, chest pain, and dyspnea in the QLQ LC13 was 5.8 months (95% CI: 4.40, NE) in T+PP arm and 4.3 months (95 %CI: 3.09, NE) in PP arm.

First-line treatment of locally advanced or metastatic squamous NSCLC in combination with carboplatin and either paclitaxel or nab-paclitaxel chemotherapy

The efficacy of tislelizumab was evaluated in RATIONALE-307 (NCT03594747), a multicenter, randomized, open-label, phase 3 study comparing the efficacy and safety of tislelizumab combined with paclitaxel plus carboplatin or nab-paclitaxel plus carboplatin versus paclitaxel plus carboplatin alone as first-line treatment for untreated locally advanced squamous NSCLC patients who were not candidates for surgical resection or platinum based chemoradiation or metastatic NSCLC patients.

The study excluded patients who have active brain or leptomeningeal metastases, known EGFR mutations or ALK translocations sensitive to available targeted inhibitor therapy, active autoimmune disease, or any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive treatments.

A total of 360 patients were randomized (1:1:1) to receive tislelizumab 200 mg combined with paclitaxel 175 mg/m² and carboplatin AUC 5 mg/ml/min (T+PC arm, N = 120), or tislelizumab 200 mg combined with nab-paclitaxel 100 mg/m² and carboplatin AUC 5 mg/mL/min (T+nPC arm, N = 119), or paclitaxel 175 mg/m² and carboplatin AUC 5 mg/mL/min (PC, N = 121 arm).

The treatment was administered on a 3-week cycle, until the patient completed administration of 4 to 6 cycles of chemotherapy or tislelizumab combined with chemotherapy at the investigator's discretion. Patients in T+nPC and T+PC arms received tislelizumab until disease progression or unacceptable toxicity; while tislelizumab monotherapy could continue beyond disease progression if the patient was deriving clinical benefit as assessed by the investigator. Patients in the PC arm with disease progression were given the option to cross over to receive tislelizumab monotherapy on a 3-week cycle.

Randomization was stratified by PD-L1 tumour cell (TC) score (<1% versus 1% to 49% versus $\geq 50\%$) and tumour staging (IIIB versus IV) as classified according to American Joint Committee on Cancer (AJCC), 7th edition of Cancer Staging Manual. PD-L1 expression was evaluated at a central laboratory using the Ventana PD-L1 (SP263) assay that identified PD-L1 staining on tumour cells. Tumour assessments were conducted every 6 weeks for the first 6 months, then every 9 weeks for the next 6 months, then every 12 weeks until disease progression.

The baseline characteristics for the study population were: median age 62.0 years (range: 34 to 74 years), 35.3% with 65 years of age or older; 91.7% male; 100% Asian, 23.6% with ECOG PS of 0 and 76.4% with ECOG PS of 1; 33.9% diagnosed with stage IIIB and 66.1% with stage IV at baseline; 16.4% never-smokers; 38.8% with PD-L1 TC score <1%, 25.3% with PD-L1 TC score $\geq 1\%$ and $\leq 49\%$, 34.7% with PD-L1 TC score $\geq 50\%$. The characteristics of age, sex, ECOG PS, stage, smoking status, PD-L1 TC score and prior anticancer treatments were well balanced.

The primary efficacy endpoint was progression-free survival (PFS) as assessed by IRC per RECIST v1.1 in the intention-to-treat (ITT) analysis which was to be tested sequentially in arms T+PC versus PC and arms T+nPC versus PC. The secondary endpoints included overall survival (OS), objective response rate (ORR) and duration of response (DoR) per IRC and per investigator.

The study met its primary endpoint at the interim analysis (data cut-off date of 06-Dec-2019 and a median duration of study follow-up of 8.4 months), showing statistically significant improvement in PFS with tislelizumab in combination with paclitaxel and carboplatin (T+PC arm) and tislelizumab in combination with nab-paclitaxel and carboplatin (T+nPC arm) compared with paclitaxel and carboplatin alone (PC arm). The stratified HR (T+PC arm versus PC arm) was 0.48 (95% CI: 0.34, 0.69; $p < 0.0001$), indicating a 52% risk reduction in disease progression or death. The stratified HR was 0.45 (95% CI: 0.32, 0.64; $p < 0.0001$), a 55% risk reduction in disease progression or death was observed when comparing T+nPC arm with PC arm, with a median PFS of 7.6 months with T+PC arm and 7.6 months with T+nPC arm and 5.4 months with P+C arm. The final analysis (data cut-off date of 30-Sep-2020 and a median duration of study follow-up of 16.7 months) confirmed the results from the interim analysis.

Efficacy results for the final analysis are shown in Table 15, Figure 4 and Figure 5.

Table 15 Efficacy results in RATIONALE-307 by IRC

Endpoint	tislelizumab + Paclitaxel + Carboplatin (N = 120)	tislelizumab + nab-Paclitaxel + Carboplatin (N = 119)	Paclitaxel + Carboplatin (N = 121)
PFS			
Events, n (%)	80 (66.7)	79 (66.4)	86 (71.1)
Median PFS (months) (95% CI)	7.7 (6.7, 10.4)	9.6 (7.4, 10.8)	5.5 (4.2, 5.6)
Stratified hazard ratio ^a (95% CI)	0.45 (0.33, 0.62)	0.43 (0.31, 0.60)	-
PFS event-free rate, (%) (95% CI)			
12 months	36.5 (27.6, 45.4)	33.1 (24.2, 42.3)	9.5 (4.5, 16.8)
18 months	29.4 (20.8, 38.4)	27.1 (18.7, 36.2)	6.8 (2.7, 13.6)
OS			
Deaths n (%)	48 (40.0)	47 (39.5)	52 (43.0)
Median OS (months) (95% CI)	22.8 (19.1, 26.1)	NE (18.6, NE)	20.2 (16.0, NE)
Stratified hazard ratio (95% CI)	0.68 (0.46, 1.010)	0.75 (0.50, 1.12)	-
OS event-free rate, (%) (95% CI)			
12 months	72.7 (63.7, 79.9)	77.3 (68.4, 83.9)	71.4 (61.9, 79.0)

Endpoint	tislelizumab + Paclitaxel + Carboplatin (N = 120)	tislelizumab + nab-Paclitaxel + Carboplatin (N = 119)	Paclitaxel + Carboplatin (N = 121)
18 months	63.2 (53.8, 71.2)	62.0 (52.1, 70.4)	55.7 (45.3, 64.8)
ORR^b			
ORR, n (%)	74 (61.7)	74 (62.2)	45 (37.2)
95% CI	(52.4, 70.4)	(52.8, 70.9)	(28.6, 46.4)
CR, n (%)	7 (5.8)	6 (5.0)	1 (0.8)
PR, n (%)	67 (55.8)	68 (57.1)	44 (36.4)
DoR^b			
Median DoR (months) (95% CI)	13.2 (7.85, 18.79)	10.4 (8.34, 17.15)	4.8 (4.04, 5.72)
Event-free rate, (%) (95% CI)^c			
6-months	68.3 (56.23, 77.66)	77.9 (66.44, 85.81)	35.2 (20.94, 49.74)
12-months	51.0 (38.87, 61.92)	45.8 (33.79, 57.09)	19.8 (9.14, 33.37)
18-months	44.8 (32.31, 56.48)	30.4 (18.61, 42.97)	11.9 (3.56, 25.62)


Abbreviations: PFS = progression-free survival; CI = confidence interval; ORR = objective response rate; CR = complete response; PR = partial response; DoR = duration of response; NE = not estimable.

^a Stratified by stratification factors: disease stage (IIIB versus IV) and PD-L1 score in tumour cell ($\geq 50\%$ versus 1% - 49% versus $< 1\%$).

^b Confirmed response by independent review committee

^c Event free rates evaluated by Kaplan-Meier method with 95% CI estimated using Greenwood's formula.

Figure 4 Kaplan-Meier plot of PFS in RATIONALE-307 by IRC




Hazard ratio based on stratified analysis

Abbreviations: CI = Confidence Interval; T+PC = Tislelizumab + Paclitaxel + Carboplatin; PC = Paclitaxel + Carboplatin.

Figure 5 Kaplan-Meier plot of PFS in RATIONALE 307 by IRC

T+nPC arm vs. PC arm



Hazard ratio based on stratified analysis

Abbreviations: CI = Confidence Interval; T+nPC = Tislelizumab + nab-Paclitaxel + Carboplatin; PC = Paclitaxel + Carboplatin.

Subgroup analyses demonstrated a homogeneous and generally consistent PFS treatment effect across major demographic and prognostic subgroups, including PD-L1 expression, and disease stages IIIB and IV:

- for T+PC, with PFS HR of 0.38 (95% CI, HR = 0.22, 0.67) for stage IIIB and 0.51 (95% CI, 0.35, 0.75) for stage IV.

- for T+nPC, with PFS HR of 0.40 (95% CI, HR = 0.24, 0.67) for stage IIIB and 0.50 (95% CI, 0.33, 0.74) for stage IV.

Efficacy results of PFS by tumour PD-L1 expression in pre-specified subgroup analyses are shown in Table 16.

Table 16 Efficacy results of PFS by tumour PD-L1 expression in study BGB-A317-307

	tislelizumab + Paclitaxel + Carboplatin arm (N = 120)	Paclitaxel + Carboplatin arm (N = 121)	tislelizumab + Paclitaxel + Carboplatin arm (N = 119)	Paclitaxel + Carboplatin arm (N = 121)
PD-L1 expression in tumour cell <1%, n	47	45	46	45
Events, n (%)	31 (66.0)	31 (68.9)	35 (76.1)	31 (68.9)
Median PFS (months), (95% CI)	7.6 (5.5, 14.5)	5.5 (4.2, 7.0)	7.6 (5.4, 9.9)	5.5 (4.2, 7.0)
Hazard ratio (95% CI)	0.57 (0.34, 0.94)		0.65 (0.39, 1.05)	
PD-L1 expression in tumour cell 1% to 49%, n	30	31	30	31
Events, n (%)	18 (60.0)	24 (77.4)	20 (66.7)	24 (77.4)
Median PFS (months)	10.4 (5.5, 20.0)	5.0 (2.8, 6.5)	10.1 (7.4, 12.0)	5.0 (2.8, 6.5)
Hazard ratio (95% CI)	0.40 (0.21, 0.76)		0.40 (0.21, 0.74)	
PD-L1 expression in tumour cell ≥50%, n	42	41	42	41
Events, n (%)	31 (73.8)	29 (70.7)	23 (54.8)	29 (70.7)
Median PFS (months)	7.7 (5.9, 9.8)	5.5 (4.1, 7.0)	9.7 (5.6, NE)	5.5 (4.1, 7.0)
Hazard ratio ^a (95% CI)	0.44 (0.26, 0.75)		0.33 (0.18, 0.59)	

^a Hazard ratio and its 95% CI was estimated from unstratified Cox model

Patient reported outcomes/Quality of life

PROs were collected using the EORTC-QLQ-C30 questionnaire. Completion rates among all treatment arms were >99% at baseline and remained 97% through cycle 5.

The baseline EORTC QLQ-C30 global health status/QoL scores were similar for the 3 treatment arms. Patients in T+PC and T+nPC arms had similar HRQoL outcomes to those in PC arm as measured by the QLQ-C30 global health status/QoL and by lung cancer-specific symptoms of cough, chest pain and dyspnea.

The median TTD for QLQ-C30 global health status/QoL was not reached in all treatment arms; the median TTD for the composite of cough, chest pain, and dyspnea scores was reached in P+PC arm and was 5.7 months (95% CI: 3.06, NE).

Previously Treated Non-Small Cell Lung Cancer

The efficacy of tislelizumab was evaluated in RATIONALE-303 (NCT03358875) a multicenter, randomized, open-label, phase 3 study in patients with locally advanced or metastatic NSCLC (squamous or non-squamous), who had experienced disease progression on or after a prior platinum-containing regimen. The study excluded patients with known EGFR mutation or ALK rearrangement, active autoimmune disease, or any condition requiring systemic treatment with either corticosteroids (>10 mg daily of prednisone or equivalent) or other immunosuppressive treatments.

A total of 805 patients were randomized (2:1) ratio to receive tislelizumab 200 mg intravenously every 3 weeks (N = 535) or docetaxel 75 mg/m² intravenously every 3 weeks (N = 270).

Randomization was stratified by histology (squamous versus non-squamous), lines of therapy (second- versus third-line), and PD-L1 expression in tumour cells (TC) ($\geq 25\%$ versus $< 25\%$). Administration of docetaxel and tislelizumab continued until disease progression, as assessed by investigator per RECIST v1.1, or unacceptable toxicity. PD-L1 expression was evaluated at a central laboratory using the VentanaPD-L1 (SP263) assay that identified PD-L1 staining on tumour cells. Tumour assessments were conducted every 9 weeks for 52 weeks after randomization and continued every 12 weeks thereafter. Survival status was followed every 3 months after discontinuation of the study treatment.

The baseline characteristics for the study population were: median age 61 years (range: 28 to 88 years), 32.4% with 65 years of age or older, 3.2% with 75 years of age or older; 77.3% male; 17.0% White and 79.9% Asian; 20.6% with ECOG PS of 0 and 79.4% with ECOG PS of 1; 85.5% with metastatic disease; 30.3% never smokers; 46.0% with squamous and 54.0% non-squamous histology; 65.8% with wild-type and 34.0% with unknown EGFR status; 46.1% with wild-type and 53.9% with unknown ALK status; 7.1% with brain metastases.

57.0% of the patients had aPD-L1 TC score $\leq 25\%$, and 42.5% had a PD-L1 TC score $\geq 25\%$. All patients had received prior therapy with a platinum-doublet regimen, 84.7% patients received one prior therapy, and 15.3% had received two prior therapies. The co-primary efficacy endpoints were OS in the ITT and PD-L1 TC score $\geq 25\%$ analysis sets. Additional endpoints included investigator assessed PFS, ORR, and DoR.

RATIONALE-303 met both its co-primary endpoints of OS in the ITT analysis set and PD-L1 TC $\geq 25\%$ analysis set. At the prespecified interim analysis (data cut-off 10-Aug-2020 with a median duration of study follow-up time of 11.7 months), a statistically significant and clinically meaningful improvement in OS was observed in the ITT population. Results favored treatment with tislelizumab, with a 36% relative risk reduction relative to docetaxel (HR = 0.64; 95% CI: 0.53, 0.78; $p < 0.0001$). Median OS was prolonged by 5.3 months, from 11.9 months for patients receiving docetaxel to 17.2 months for tislelizumab-treated patients.

The final analysis (data cut-off date of 15-Jul-2021 and a median duration of study follow-up of 14.2 months) showed consistent efficacy results in the ITT population compared to the interim analysis.

At the final analysis, a statistically significant and clinically meaningful improvement in OS of tislelizumab compared with docetaxel was observed in the PD-L1 TC $\geq 25\%$ analysis set, with a one-sided stratified $p < 0.0001$. Results favored treatment with tislelizumab, with a 47% relative risk reduction in death relative to docetaxel (HR = 0.53; 95% CI: 0.41, 0.70) in the PD-L1 TC $\geq 25\%$ population, and a clinically meaningful improvement for median OS from 11.5 months (95% CI: 8.15, 13.54 months) in the docetaxel arm to 19.3 months (95% CI: 16.49, 22.60 months) in the tislelizumab arm.

Efficacy results for the interim and final analysis are shown in Table 17 (ITT analysis set) and Table 18 (PD-L1 TC $\geq 25\%$ analysis set), Figures 6 and 7 (ITT analysis set) and Figure 8 (PD-L1 TC $\geq 25\%$ analysis set).

Table 17 Efficacy results in RATIONALE 303 (ITT analysis set)

Endpoint	tislelizumab (N = 535)	Docetaxel (N = 270)
Interim analysis (data cut-off date of 10 Aug 2020)		
OS		
Deaths n (%)	275 (51.4)	166 (61.5)
Median OS (months) (95% CI)	17.2 (15.28, 20.04)	11.9 (10.18, 13.93)

Endpoint	tislelizumab (N = 535)	Docetaxel (N = 270)
Hazard ratio (95% CI) ^b	0.64 (0.53, 0.78)	
P-value (stratified log-rank) ^a	<0.0001	
OS event-free rate, (%) (95% CI)		
12 months	61.9 (57.5, 66.0)	49.8 (43.4, 55.9)
18 months	48.4 (43.7, 53.0)	31.9 (25.5, 38.6)
24 months	39.4 (34.1, 44.6)	25.0 (18.4, 32.2)
PFS		
Events, n (%)	418 (78.1)	200 (74.1)
Median PFS in months (95% CI)	4.1 (3.75, 5.03)	2.6 (2.17, 3.78)
Hazard Ratio ^b (95% CI)	0.64 (0.53, 0.76)	
ORR (%) (95% CI)^c	20.0 (16.69, 23.64)	3.7 (1.79, 6.71)
Best overall response^c		
CR (%)	1.3	0.4
PR (%)	18.7	3.3
SD (%)	32.0	37.0
DoR^d		
Median (months) (95% CI)	14.5 (10.18, NE)	6.7 (4.11, NE)
Event-free rate (%), (95% CI)^d		
6-months	83.7 (74.73, 89.67)	87.5 (38.70, 98.14)
12-months	56.3 (44.93, 66.27)	25.0 (3.71, 55.81)
Final Analysis (data cut-off date of 15 Jul 2021)		
OS		
Deaths n (%)	365 (68.2)	206 (76.3)
Median OS (months) (95% CI)	16.9 (15.24, 19.09)	11.9 (9.63, 13.54)
Hazard ratio (95% CI) ^{a,b}	0.66 (0.56, 0.79)	
OS event-free rate, (%) (95% CI)		
12 months	62.1 (57.86, 66.13)	49.7 (43.45, 55.71)
18 months	47.5 (43.12, 51.67)	32.6 (26.94, 38.45)
24 months	36.8 (32.62, 41.01)	23.7 (18.57, 29.17)
36 months	24.7 (20.29, 29.43)	13.8 (8.87, 19.69)
PFS		
Events, n (%)	451 (84.3)	208 (77.0)
Median PFS in months (95% CI)	4.2 (3.88, 5.52)	2.6 (2.17, 3.78)
Hazard Ratio ^{a,b} (95% CI)	0.63 (0.53, 0.75)	
ORR (%) (95% CI)^c	20.9 (17.56, 24.63)	3.7 (1.79, 6.71)
Best overall response^c		
CR (%)	1.7	0.4
PR (%)	19.3	3.3
SD (%)	31.0	37.0
DoR		
Median (months) (95% CI)	14.7 (10.55, 21.78)	6.2 (4.11, 8.31)
Event-free rate (%), (95% CI)		
6-months	84.5 (76.21, 90.05)	80.0 (40.87, 94.59)
12-months	56.5 (46.45, 65.35)	20.0 (3.09, 47.47)

Abbreviations: OS = overall survival; CI = confidence interval; PFS = progression-free survival; ORR = objective response rate; CR = complete response; PR = partial response; SD = stable disease; DoR = duration of response; NE=Not estimable.

Medians were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

Endpoint	tislelizumab (N = 535)	Docetaxel (N = 270)
^a Stratified by stratification factors: histology (squamous versus non-squamous), lines of therapy (second versus third), and PD-L1 expression in tumour cell ($\geq 25\%$ PD-L1 score versus $< 25\%$ PD-L1 score).		
^b Hazard ratio was estimated from stratified Cox model with docetaxel as reference group.		
^c Confirmed response by investigator		
^d Event free rates were estimated by Kaplan-Meier method with 95% CI evaluated using Greenwood's formula.		

Table 18 Efficacy results in BGB-A317-303 (PD-L1 TC $\geq 25\%$ analysis set) (data cut-off date of 15-Jul-2021)

Endpoint	TEVIMBRA (N = 227)	Docetaxel (N = 115)
OS		
Deaths n (%)	141 (62.1)	86 (74.8)
Median OS (months) (95% CI)	19.3 (16.49, 22.60)	11.5 (8.15, 13.54)
Hazard ratio (95% CI) ^a	0.53 (0.41, 0.70)	
OS event-free rate, (%) (95% CI)		
12 months	67.4 (60.83, 73.11)	48.3 (38.51, 57.38)
18 months	52.8 (45.98, 59.10)	30.0 (21.49, 38.87)
24 months	42.3 (35.62, 48.82)	22.6 (14.98, 31.10)

Median follow-up time was estimated by the reverse Kaplan-Meier method.

Medians and other quartiles were estimated by Kaplan-Meier method with 95% CIs estimated using the method of Brookmeyer and Crowley.

Event free rates were estimated by Kaplan-Meier method with 95% CIs estimated using the Greenwood's formula.

Docetaxel arm was the reference group for hazard ratio.

^a Stratified by stratification factors: histology (squamous versus non-squamous), lines of therapy (second versus third).

Figure 6 Kaplan-Meier plot of OS in RATIONALE-303 (ITT analysis Set) (data cut-off date of 10-Aug-2020)




Figure 7 Kaplan-Meier plot of OS in BGB-A317-303 (PD-L1 TC \geq 25% analysis set) (data cut-off date of 15-Jul-2021)





Figure 8 Kaplan-Meier plot of OS in BGB-A317-303 (PD-L1 TC \geq 25% analysis set) (data cut-off date of 15-Jul-2021)



At the interim and final analyses, prespecified subgroup analyses demonstrated a consistent OS treatment effect in favour of tislelizumab across major demographic and prognostic subgroups, including race, PD-L1 expression, histology and line of therapy.

At the interim analysis, consistent treatment benefit was observed in both race types, with OS HR of 0.62 (95% CI, HR = 0.51, 0.77) for Asian and OS HR of 0.61 (95% CI, HR = 0.34, 1.08) for White patients. OS benefits were observed in both histological types, with OS HR of 0.58 (95% CI: 0.44, 0.76) for squamous NSCLC and OS HR of 0.71 (95% CI: 0.54, 0.93) for non-squamous NSCLC.

The final analysis confirmed consistent treatment benefit in both race types with OS HR of 0.66 (95% CI, HR = 0.54, 0.79) for Asian vs. 0.63 (95% CI, HR = 0.41, 0.98) for White patients. Consistent OS benefits were observed in both histological types as well, with OS HR of 0.60 (95% CI: 0.47, 0.77) for squamous NSCLC vs. 0.72 (95% CI: 0.56, 0.91) for non-squamous NSCLC.

Figure 9, Figure 10, Figure 11 and Figure 12 summarise efficacy results of OS by tumour PD-L1 expression in prespecified subgroup analyses.

Figure 9 Efficacy results of OS by tumour PD-L1 expression in BGB-A317-303 (data cut-off date 10-Aug-2020)




Figure 10 Efficacy results of OS by tumour PD-L1 expression in study BGB-A317-303 (data cut-off date of 15-Jul-2021)




Figure 11 Forest plot of OS by subgroups in BGB-A317-303 (ITT analysis set) (data cut-off date of 10-Aug-2020)







Figure 12 Forest plot of OS by subgroups in BGB-A317-303 (ITT analysis set) (data cut-off date of 15-Jul-2021)



PROs were collected using EORTC-QLQ-C30, QLQ-LC13 and EQ-5D-5L questionnaires. At the interim analysis, completion rates for all the 3 questionnaires were similar in both treatment arms, with compliance rates of >98% to 100% for QLQ-C30 and QLQ-LC13 and 78% to 100% for EQ-5D-5L.

Tislelizumab trended towards improvements in HRQoL compared to docetaxel in patients with NSCLC who had progressed on a prior platinum-containing regimen.

The tislelizumab arm showed improvements over time in QLQ-C30 GHS/QoL, as well as physical function, fatigue in QLQ-C30. Additionally, in the tislelizumab arm, there was a trend towards improvement in coughing, dyspnea and pain symptoms of the QLQ-C13 compared to docetaxel arm.

The change from baseline scores of EQ-5D-5L in the descriptive domain's total score as well as the visual analogue scale showed better outcomes in the tislelizumab Arm.

The median time to deterioration (TTD) for QLQ-C30 GHS/QoL and for the index score of the QLQ-LC13 was not reached in either treatment arm.

At the final analysis, compliance rates for all 3 questionnaires were similar in both treatment arms, with compliance rates of >96% to 100% for QLQ-C30 and QLQ-LC13 and >75% for EQ-5D-5L. Compliance rates of QoL assessments remained above 75% at baseline and during cycles 4 and 6.

The tislelizumab arm trended towards improvement from baseline in GHS/QoL as well as fatigue and coughing compared with the docetaxel arm. Improvements were observed in fatigue and QLQ-LC13 index score assessing overall lung cancer symptoms, while physical functioning was maintained compared to patients in the docetaxel arm who experienced worsening.

A arm were observed to be at lower risk of experiencing a deterioration event compared with those in the docetaxel arm, as indicated by stratified hazard ratio of 0.77 (95% [CI:0.57, 1.03]) in GHS/QoL and 0.24 (95% [CI:0.16,0.36]) in index score of QLQ-LC13.

The change from baseline scores of EQ-5D-5L visual analogue scale (VAS) showed similar outcomes in both arms.

Gastric/Gastro-oesophageal Junction (G/GOJ) Adenocarcinoma

First-line treatment of patients with HER-2 negative locally advanced unresectable or metastatic G/GOJ adenocarcinoma in combination with platinum and fluoropyrimidine-based chemotherapy

RATIONALE-305 (NCT03777657) is a randomised, multicentre, placebo-controlled, double-blind trial in patients with previously untreated locally advanced unresectable or metastatic G/GOJ adenocarcinoma.

Patients were enrolled regardless of their tumour PD-L1 expression level, which was evaluated prospectively at a central laboratory using the VENTANA PD-L1 (SP263) assay that identified PD-L1 staining on both tumour and tumour-associated immune cells (Tumour Area Positivity (TAP) score).

The study included only patients with histologically confirmed adenocarcinoma. The trial excluded patients who had squamous cell or undifferentiated or other histological type of G/GOJ cancer; patients diagnosed with G/GOJ adenocarcinoma with known human epidermal growth factor receptor 2 (HER2) positive tumours; patients who had active leptomeningeal disease or uncontrolled brain metastasis; patients with active autoimmune disease or history of autoimmune diseases, that may relapse.

TEVIMBRA plus platinum and fluoropyrimidine based chemotherapy (T+PtF) or placebo plus platinum and fluoropyrimidine based chemotherapy (P+PtF) were administered on a 21-day cycle. TEVIMBRA (or placebo) was administered until disease progression or unacceptable toxicity.

The administration of chemotherapy agents consisted of:

- Oxaliplatin 130 mg/m² IV on Day 1, and capecitabine 1000 mg/m² orally twice daily for 14 consecutive days, repeated every 3 weeks. Oxaliplatin was administered for up to 6 cycles and capecitabine was administered as maintenance therapy at investigators discretion until disease progression or unacceptable toxicity.

Or

- Cisplatin 80 mg/m² IV on Day 1, and 5-FU 800 mg/m²/day IV continuous infusion over 24 hours daily on Day 1-5, repeated every 3 weeks. Cisplatin and 5-FU were given for up to 6 cycles.

Cross-over between treatment arms was not allowed.

Randomisation was stratified by region (China (including Taiwan), vs. Japan and South Korea vs. rest of the world (ROW), including US and Europe); PD-L1 expression (PD-L1 TAP score \geq 5% vs. PD-

L1 TAP score <5%); presence of peritoneal metastasis (yes vs. no) and ICC option (oxaliplatin plus capecitabine vs. cisplatin plus 5-FU). Additional analyses of efficacy outcome measures were also conducted based on PD-L1 TAP score $\geq 1\%$.

The primary efficacy outcome measures were OS that was tested hierarchically in the PD-L1 TAP score $\geq 5\%$ population and in the Intent-to-Treat (ITT) population. Secondary outcome measures included progression-free survival (PFS), objective response rate (ORR), and duration of response (DoR) as assessed by the investigator per RECIST v1.1. Tumour assessments were performed every 6 weeks for the first 48 weeks and thereafter approximately every 9 weeks.

A total of 997 patients were randomized to receive either tislelizumab plus platinum and fluoropyrimidine based chemotherapy (T+PtF Arm, N = 501), or placebo plus platinum and fluoropyrimidine based chemotherapy (P+PtF Arm, N = 496). Of the 997 patients, 885 (88.8%) had PD-L1 TAP score $\geq 1\%$ (T+PtF Arm, N = 432; P+PtF Arm, N = 453).

The demographics and baseline characteristics of PD-L1 TAP $\geq 1\%$ population were generally balanced in T+PtF and P+PtF arms. 34.5% patients in T+PtF Arm and 37.1% patients in P+PtF Arm were aged 65 years or older. 65.5% patients in T+PtF Arm and 68.0% patients in P+PtF Arm had ECOG performance status score of 1 at baseline. 24.8% patients in T+PtF Arm and 25.4% patients in P+PtF Arm were enrolled from US/Europe. Most patients had metastatic disease at baseline (98.6% in T+PtF Arm and 99.1% in P+PtF Arm), while 44.0% patients in T+PtF Arm and 43.3% patients in P+PtF Arm had peritoneal metastasis.

At final analysis (DCO: 28 February 2023), with a minimum follow-up time of 24.6 months, the trial met the primary endpoint of OS in the ITT analysis set, demonstrating a statistically significant and clinically meaningful improvement for the ITT population. In the PD-L1 TAP $\geq 1\%$ population, the OS HR was 0.78 (95% CI: 0.67, 0.90), with a median OS of 15.0 months (95% CI: 13.3, 16.7) for the T+C arm vs. 12.8 months (95% CI: 12.1, 14.1) for the P+C arm, showing clinical meaningful survival benefit favouring T+C arm.

The median PFS was 6.9 months in T+PtF arm and 5.9 months in P+PtF arm, with HR of 0.78 (95% HR 0.67, 0.91). The ORR was 47.7% in T+PtF arm and 41.1% in P+PtF arm, with Odds Ratio of 1.31 (95%CI: 1.00, 1.72). For patients with response, the median DoR was 8.6 months T+PtF arm and 7.2 months in P+PtF arm. Analysis of these efficacy endpoints also demonstrated better disease control in T+PtF arm in this population

Final analysis efficacy results of PD-L1 TAP $\geq 1\%$ population are shown in Table 19, and Figure 13 and 14.

Table 5 Efficacy Results in PD-L1 TAP \geq 1% population of RATIONALE-305 (final analysis)

Endpoint	T+PtF (N = 432)	P+PtF (N = 453)
OS		
Deaths, n (%)	318 (73.6)	370 (81.7)
Median (months) (95% CI)	15.0 (13.3, 16.7)	12.8 (12.1, 14.1)
Unstratified Hazard ratio (95% CI) ^a	0.78 (0.67, 0.90)	
PFS		
Disease progression or death, n (%)	316 (73.1)	364 (80.4)
Median (months) (95% CI)	6.9 (5.7, 7.2)	5.9 (5.6, 6.9)
Unstratified Hazard ratio (95% CI) ^a	0.78 (0.67, 0.91)	
ORR		
ORR, n	206	186
ORR, %	47.7	41.1
95% CI (%)	(42.9, 52.5)	(36.5, 45.7)
Unstratified Odds Ratio for ORR, (95% CI) ^b	1.31 (1.00, 1.71)	
DoR		
Median (months) (95% CI)	8.6 (7.8, 10.4)	7.2 (5.8, 8.3)


Data cutoff: 28FEB2023

CI = confidence interval; : T+PtF = Tislelizumab + Platinum fluoropyrimidine based chemotherapy; P+PtF = Placebo + Platinum fluoropyrimidine based chemotherapy; PD-L1 = programmed cell death protein ligand-1; DoR = Duration of response; ORR = objective response rate; OS = overall survival; PFS = progression-free survival.

^a Unstratified OS: Hazard ratio was estimated from Cox model with P+PtF arm as the reference group.

^b Unstratified odds ratios between arms were calculated using the unstratified Cochran-Mantel-Haenszel method.

Figure 13 Kaplan-Meier Curve for Overall Survival in PD-L1 TAP \geq 1% population of RATIONALE-305 (final analysis)




Data cutoff: 28FEB2023.

Arm A = Tislelizumab + Platinum fluoropyrimidine based chemotherapy, Arm B = Placebo + Platinum fluoropyrimidine based chemotherapy; PD-L1 = programmed cell death protein ligand-1.

Hazard ratio was based on unstratified Cox regression model.

'+' = censored.

Figure 14 Kaplan-Meier Curve for Progression-Free Survival in PD-L1 TAP \geq 1% population of RATIONALE-305 (final analysis)



Data cutoff: 28FEB2023.

Arm A = Tislelizumab + Platinum fluoropyrimidine based chemotherapy, Arm B = Placebo + Platinum fluoropyrimidine based chemotherapy; PD-L1 = programmed cell death protein ligand-1.

Hazard ratio was based on unstratified Cox regression model.

'+' = censored.

5.2 PHARMACOKINETICS PROPERTIES

The pharmacokinetics (PK) of tislelizumab was assessed for tislelizumab both as monotherapy and in combination with chemotherapy.

The PK of tislelizumab was characterized using population PK analysis with concentration data from 2,596 patients with advanced malignancies who received tislelizumab doses of 0.5 to 10 mg/kg every 2 weeks, 2.0 and 5.0 mg/kg every 3 weeks, and 200 mg every 3 weeks.

Tislelizumab exhibited linear PK in the dose range tested (0.5 mg/kg to 10 mg/kg, including 200 mg flat dose). The time to reach 90% steady-state level is approximately 84 days (12 weeks) after 200 mg once every 3 weeks (Q3W) doses, and the steady-state accumulation ratio of tislelizumab PK exposure is approximately 2-fold.

Absorption

Tislelizumab is administered via the intravenous route and therefore is immediately and completely bioavailable.

Distribution

A population pharmacokinetic analysis indicates that the steady state volume of distribution is 6.42 L, which is typical of monoclonal antibodies with limited distribution.

Biotransformation

Tislelizumab is expected to be degraded into small peptides and amino acids via catabolic pathways.

Elimination

Based on population PK analysis, the clearance of tislelizumab was 0.153 L/day with an inter-individual variability of 26.3% and the geometrical mean terminal half-life was approximately 23.8

days with a coefficient variation (CV) of 31%. Time-varying clearance was not observed in tislelizumab PK.

Linearity/non-linearity

At the dosing regimens of 0.5 mg/kg to 10 mg/kg once every 2 or 3 weeks (including 200 mg once every 3 weeks), PK of tislelizumab were observed to be linear and dose proportional, suggesting saturation of the target-mediated pathway.

Special populations

The effects of various covariates on the PK of tislelizumab were assessed in population PK analyses. The following factors had no clinically relevant effect on the exposure of tislelizumab: age (range 18 to 90 years), weight (range 32 to 130 kg), gender, race (White, Asian, and other), mild to moderate renal impairment (creatinine clearance (CL_{Cr}) ≥30 mL/min), mild to moderate hepatic impairment (total bilirubin ≤3 times ULN and any AST), and tumour burden.

Elderly patients

Of 2,596 patients who received tislelizumab as monotherapy or combination therapies, 1,750 patients (67.4%) were <65 years and 846 (32.6%) patients were ≥65 years of age, 737 (28.4%) patients between 65 and 75 years, and 109 (4.2%) patients >75 years).

Based on population PK and exposure- response analysis, no clinically relevant differences in PK or safety or efficacy of tislelizumab were observed between patient's aged <65 years, patients aged between 65 and 75 years and patients aged >75 years (see section 4 Dosage regimen and administration).

Patients with renal impairment

No dedicated studies of tislelizumab have been conducted in patients with renal impairment. In the population PK analyses of tislelizumab, no clinically relevant differences in the clearance of tislelizumab were found between patients with mild renal impairment (CL_{Cr} 60 to 89 mL/min, n=1,046) or moderate renal impairment (CL_{Cr} 30 to 59 mL/min, n=320) or severe renal impairment (CL_{Cr} 15 to 29 mL/min, n=5) and patients with normal renal function (CL_{Cr} ≥90 mL/min, n=1223). Mild and moderate renal impairment had no effect on the exposure of tislelizumab (see section 4 Dosage regimen and administration).

Patients with hepatic impairment

No dedicated studies of tislelizumab have been conducted in patients with hepatic impairment. In the population PK analyses of tislelizumab, no clinically important differences in the clearance of tislelizumab were found between patients with mild hepatic impairment (bilirubin ≤ULN and AST >ULN or bilirubin >1.0 to 1.5 × ULN and any AST, n=396), moderate hepatic impairment (bilirubin >1.5 to 3 × ULN and any AST, n=12), compared to patients with normal hepatic function (bilirubin ≤ULN and AST ≤ULN, n=2,182) (see section 4.2 Dose and method of administration). Based on the limited number of patients with severe hepatic impairment (n=2), the effect of severe hepatic impairment on the pharmacokinetics of tislelizumab is unknown.

Hepatic impairment was defined by the National Cancer Institute-Organ Dysfunction Working Group (NCI-ODWG) criteria of hepatic dysfunction.

5.3 PRECLINICAL SAFETY DATA

Tislelizumab was evaluated in single- and repeated-dose toxicity studies including safety pharmacology endpoints.

In a repeat-dose toxicology study in cynomolgus monkeys, following intravenous infusion at 3, 10, or 30 mg/kg (once every 2 weeks (Q2W), 7 doses) for 13 weeks, no apparent treatment-related toxicity or histopathological changes were observed in any tissues or organs, including the reproductive system of male and females. However, many of the monkeys in these studies were not sexually mature and thus no explicit conclusions regarding effects on reproductive organs can be made. No specific concerns were identified regarding vital functions, including cardiovascular system, central nervous system, and respiratory system.

Reproductive toxicity/Fertility

No developmental and reproductive toxicity studies or animal fertility studies have been conducted with tislelizumab. Literature based data are reported in section 4.6 Pregnancy, breastfeeding and fertility.

Animal toxicology and/or Pharmacology

In animal models, inhibition of PD-1 signaling resulted in an increased severity of some infections and enhanced inflammatory responses. PD-1 knockout mice infected with certain bacterial (e.g., mycobacterium tuberculosis) and viral pathogens (e.g., lymphocytic choriomeningitis) exhibited an increased severity of infection and enhanced inflammatory responses.

Carcinogenicity and mutagenicity or genotoxicity

No studies have been performed to assess the potential of tislelizumab for carcinogenicity or genotoxicity.

6 PHARMACEUTICAL PARTICULARS

6.1 LIST OF EXCIPIENTS

Sodium citrate dihydrate, citric acid monohydrate, histidine hydrochloride monohydrate, histidine, trehalose dihydrate, polysorbate-20, and water for injection (WFI).

6.2 INCOMPATIBILITIES

This product must not be mixed with products except sodium chloride, which is used to prepare diluted solution.

6.3 SHELF LIFE

Unopened vial

In New Zealand, information on the shelf life can be found on the Medsafe Product Detail public summary. The expiry date can be found on the packaging.

After opening

Once opened, the medicinal product should be diluted and infused immediately (see section 4.2 Dose and method of administration (*Instructions for use and handling* subheading) for instructions on dilution of the medicinal product before administration).

After preparation of infusion

The dilution can be stored at 2°C to 8°C for up to 24 hours. The 24 hours include storage of the diluted solution under refrigeration (2 to 8°C) for no more than 20 hours, and time required for returning to room temperature (25°C and below) as well as completing the infusion within 4 hours.

6.4 SPECIAL PRECAUTIONS FOR STORAGE

Store in a refrigerator at 2 to 8°C. Do not freeze. Store in the original carton box to protect from light.

For storage conditions after dilution of the medicinal product, see section 6.3 Shelf life.

6.5 NATURE AND CONTENTS OF CONTAINER

10mL of TEVIMBRA concentrate is provided in a 20 mL clear Type 1 glass vial, with a grey chlorobutyl stopper with FluroTec coating and seal cap with a flip-off button.

Each carton contains one vial.

6.6 SPECIAL PRECAUTIONS FOR DISPOSAL

Disposal

TEVIMBRA is for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.

6.7 PHYSIOCHEMICAL PROPERTIES

Chemical structure

TEVIMBRA (tislelizumab) is a humanized monoclonal antibody that binds with high affinity to the human programmed cell death protein 1 (PD-1). Tislelizumab is an immunoglobulin subclass 4 (IgG4) variant produced by recombinant DNA technology in Chinese hamster ovary cells, with an approximate molecular weight of 144 kDa.

CAS number

1858168-59-8

7 MEDICINE SCHEDULE (POISONS STANDARD)

Prescription only medicine

8 SPONSOR

BeiGene NZ Unlimited
c/o Quigg Partners
Level 7, The Bayleys Building
36 Brandon Street
Wellington 6011
New Zealand
Tel: 0508 196 427

9 DATE OF FIRST APPROVAL

5 December 2024

10 DATE OF REVISION

25 May 2026

SUMMARY TABLE OF CHANGES

Section Changed	Summary of new information
4.2	Dose and administration section revised
4.9	Overdose section revised